US20220233515A1 - Pharmaceutical Composition - Google Patents
Pharmaceutical Composition Download PDFInfo
- Publication number
- US20220233515A1 US20220233515A1 US17/668,811 US202217668811A US2022233515A1 US 20220233515 A1 US20220233515 A1 US 20220233515A1 US 202217668811 A US202217668811 A US 202217668811A US 2022233515 A1 US2022233515 A1 US 2022233515A1
- Authority
- US
- United States
- Prior art keywords
- compound
- pharmaceutical composition
- cellulose
- mixture
- inert substrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 97
- 239000000203 mixture Substances 0.000 claims abstract description 242
- 239000011230 binding agent Substances 0.000 claims abstract description 67
- 239000000758 substrate Substances 0.000 claims abstract description 64
- 150000003839 salts Chemical class 0.000 claims abstract description 54
- VYLOOGHLKSNNEK-JWTNVVGKSA-N 2-[(1R,5S)-3-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid Chemical compound C([C@]1(CC[C@@](C2)(N1C=1SC3=CC(=CC(F)=C3N=1)C(O)=O)[H])[H])C2OCC1=C(C2CC2)ON=C1C1=CC=CC=C1OC(F)(F)F VYLOOGHLKSNNEK-JWTNVVGKSA-N 0.000 claims abstract description 41
- 238000004519 manufacturing process Methods 0.000 claims abstract description 31
- 239000003814 drug Substances 0.000 claims abstract description 26
- 239000002245 particle Substances 0.000 claims description 90
- 238000000034 method Methods 0.000 claims description 63
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 56
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 50
- 230000008569 process Effects 0.000 claims description 44
- 239000002775 capsule Substances 0.000 claims description 39
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 38
- 239000002552 dosage form Substances 0.000 claims description 37
- 239000003826 tablet Substances 0.000 claims description 37
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 36
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 36
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 35
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 35
- 239000008101 lactose Substances 0.000 claims description 35
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 30
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 30
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 30
- 239000000463 material Substances 0.000 claims description 27
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 25
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 25
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 25
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 25
- 239000011247 coating layer Substances 0.000 claims description 24
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 23
- 206010008635 Cholestasis Diseases 0.000 claims description 21
- 230000007870 cholestasis Effects 0.000 claims description 21
- 231100000359 cholestasis Toxicity 0.000 claims description 21
- 238000002156 mixing Methods 0.000 claims description 20
- 229920001223 polyethylene glycol Polymers 0.000 claims description 19
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 18
- 229930195725 Mannitol Natural products 0.000 claims description 18
- 239000002202 Polyethylene glycol Substances 0.000 claims description 18
- 235000010355 mannitol Nutrition 0.000 claims description 18
- 239000000594 mannitol Substances 0.000 claims description 18
- 239000003586 protic polar solvent Substances 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 17
- 239000011248 coating agent Substances 0.000 claims description 15
- 238000000576 coating method Methods 0.000 claims description 15
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 15
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 14
- 239000003960 organic solvent Substances 0.000 claims description 14
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 13
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 12
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 12
- 208000035475 disorder Diseases 0.000 claims description 12
- 206010016654 Fibrosis Diseases 0.000 claims description 10
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 10
- 229960003943 hypromellose Drugs 0.000 claims description 10
- 229920000609 methyl cellulose Polymers 0.000 claims description 10
- 235000010981 methylcellulose Nutrition 0.000 claims description 10
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 9
- 230000007882 cirrhosis Effects 0.000 claims description 9
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 9
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 9
- 239000001923 methylcellulose Substances 0.000 claims description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 9
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 9
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 8
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 8
- 229920003064 carboxyethyl cellulose Polymers 0.000 claims description 8
- 229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 claims description 8
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 8
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 8
- 206010049055 Cholestasis of pregnancy Diseases 0.000 claims description 7
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 7
- 208000012347 Parenteral nutrition associated liver disease Diseases 0.000 claims description 7
- 208000033147 Parenteral nutrition-associated cholestasis Diseases 0.000 claims description 7
- 229920001800 Shellac Polymers 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 7
- 229940011871 estrogen Drugs 0.000 claims description 7
- 239000000262 estrogen Substances 0.000 claims description 7
- 239000004208 shellac Substances 0.000 claims description 7
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 7
- 229940113147 shellac Drugs 0.000 claims description 7
- 235000013874 shellac Nutrition 0.000 claims description 7
- 239000008107 starch Substances 0.000 claims description 7
- 235000019698 starch Nutrition 0.000 claims description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 6
- 239000008185 minitablet Substances 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- 229920002554 vinyl polymer Polymers 0.000 claims description 6
- 229910002011 hydrophilic fumed silica Inorganic materials 0.000 claims description 5
- 239000003613 bile acid Substances 0.000 abstract description 20
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 abstract description 19
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 abstract description 19
- 150000001875 compounds Chemical class 0.000 description 215
- 238000009472 formulation Methods 0.000 description 80
- 238000004090 dissolution Methods 0.000 description 34
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 30
- 229940126062 Compound A Drugs 0.000 description 19
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 19
- 239000000243 solution Substances 0.000 description 18
- 239000000546 pharmaceutical excipient Substances 0.000 description 17
- 235000019359 magnesium stearate Nutrition 0.000 description 15
- 102100038495 Bile acid receptor Human genes 0.000 description 14
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 description 14
- 238000011282 treatment Methods 0.000 description 13
- 238000009826 distribution Methods 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 12
- 238000000634 powder X-ray diffraction Methods 0.000 description 12
- 238000004626 scanning electron microscopy Methods 0.000 description 12
- 239000007921 spray Substances 0.000 description 12
- 241000282414 Homo sapiens Species 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 238000000113 differential scanning calorimetry Methods 0.000 description 10
- -1 retinoids Chemical class 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 229920002785 Croscarmellose sodium Polymers 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000007903 gelatin capsule Substances 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 238000007906 compression Methods 0.000 description 8
- 230000006835 compression Effects 0.000 description 8
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 8
- 239000008187 granular material Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 102100031734 Fibroblast growth factor 19 Human genes 0.000 description 7
- 101000846394 Homo sapiens Fibroblast growth factor 19 Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 238000001069 Raman spectroscopy Methods 0.000 description 7
- 239000000556 agonist Substances 0.000 description 7
- 239000007884 disintegrant Substances 0.000 description 7
- 229960001375 lactose Drugs 0.000 description 7
- 239000000314 lubricant Substances 0.000 description 7
- 229960001855 mannitol Drugs 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- 239000000902 placebo Substances 0.000 description 7
- 239000007916 tablet composition Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 6
- 229920003081 Povidone K 30 Polymers 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 239000007963 capsule composition Substances 0.000 description 6
- 239000007941 film coated tablet Substances 0.000 description 6
- 230000001590 oxidative effect Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 229940032147 starch Drugs 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 229960001681 croscarmellose sodium Drugs 0.000 description 5
- 229960000913 crospovidone Drugs 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 5
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 5
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 4
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 4
- 102100027840 Acyl-CoA wax alcohol acyltransferase 1 Human genes 0.000 description 4
- 108010018763 Biotin carboxylase Proteins 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 4
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 4
- 101000698136 Homo sapiens Acyl-CoA wax alcohol acyltransferase 1 Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241001516928 Kerria lacca Species 0.000 description 4
- 102100023418 Ketohexokinase Human genes 0.000 description 4
- 108010062852 Ketohexokinase Proteins 0.000 description 4
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 4
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 4
- 238000001530 Raman microscopy Methods 0.000 description 4
- 238000001237 Raman spectrum Methods 0.000 description 4
- 102100033451 Thyroid hormone receptor beta Human genes 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 239000001506 calcium phosphate Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 229920002301 cellulose acetate Polymers 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 229940126534 drug product Drugs 0.000 description 4
- 230000029142 excretion Effects 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 239000002050 international nonproprietary name Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 4
- 238000002203 pretreatment Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000008109 sodium starch glycolate Substances 0.000 description 4
- 229920003109 sodium starch glycolate Polymers 0.000 description 4
- 229940079832 sodium starch glycolate Drugs 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 108091008762 thyroid hormone receptors ß Proteins 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- IOIZWEJGGCZDOL-RQDYSCIWSA-N 7alpha-hydroxycholest-4-en-3-one Chemical compound C([C@H]1O)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 IOIZWEJGGCZDOL-RQDYSCIWSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 3
- 229940000425 combination drug Drugs 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 3
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 229940057948 magnesium stearate Drugs 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- YKXCWZVUWWQSAV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O YKXCWZVUWWQSAV-BTVCFUMJSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- 229910002012 Aerosil® Inorganic materials 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 2
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 102000009410 Chemokine receptor Human genes 0.000 description 2
- 108050000299 Chemokine receptor Proteins 0.000 description 2
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000000802 Galectin 3 Human genes 0.000 description 2
- 108010001517 Galectin 3 Proteins 0.000 description 2
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 101001043321 Homo sapiens Lysyl oxidase homolog 1 Proteins 0.000 description 2
- 101001043352 Homo sapiens Lysyl oxidase homolog 2 Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100021948 Lysyl oxidase homolog 2 Human genes 0.000 description 2
- 102100021949 Lysyl oxidase homolog 3 Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- VYLOOGHLKSNNEK-PIIMJCKOSA-N OC(=O)c1cc(F)c2nc(sc2c1)N1[C@H]2CC[C@@H]1C[C@@H](C2)OCc1c(onc1-c1ccccc1OC(F)(F)F)C1CC1 Chemical compound OC(=O)c1cc(F)c2nc(sc2c1)N1[C@H]2CC[C@@H]1C[C@@H](C2)OCc1c(onc1-c1ccccc1OC(F)(F)F)C1CC1 VYLOOGHLKSNNEK-PIIMJCKOSA-N 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- 102000034527 Retinoid X Receptors Human genes 0.000 description 2
- 108010038912 Retinoid X Receptors Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000002300 anti-fibrosis Effects 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
- 229940038472 dicalcium phosphate Drugs 0.000 description 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000007887 hard shell capsule Substances 0.000 description 2
- CPBQJMYROZQQJC-UHFFFAOYSA-N helium neon Chemical compound [He].[Ne] CPBQJMYROZQQJC-UHFFFAOYSA-N 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 238000012317 liver biopsy Methods 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 230000010399 physical interaction Effects 0.000 description 2
- 239000006069 physical mixture Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920002744 polyvinyl acetate phthalate Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007962 solid dispersion Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 125000005591 trimellitate group Chemical group 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- MEHUJCGAYMDLEL-CABCVRRESA-N (9r,10s)-9,10,16-trihydroxyhexadecanoic acid Chemical compound OCCCCCC[C@H](O)[C@H](O)CCCCCCCC(O)=O MEHUJCGAYMDLEL-CABCVRRESA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
- BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 description 1
- UUQGEDIHHHDZII-UHFFFAOYSA-N 3-cyclopropyl-4-phenyl-1,2-oxazole Chemical group C1(=CC=CC=C1)C=1C(=NOC1)C1CC1 UUQGEDIHHHDZII-UHFFFAOYSA-N 0.000 description 1
- SPZURESODGZJAL-UHFFFAOYSA-N 4-hydroxyhexadecanoic acid Chemical compound CCCCCCCCCCCCC(O)CCC(O)=O SPZURESODGZJAL-UHFFFAOYSA-N 0.000 description 1
- WSASFFHWOQGSER-MUAIWGBPSA-N 82xgf31q2y Chemical compound C1[C@@]23[C@H](C(O)=O)CC[C@H]2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O WSASFFHWOQGSER-MUAIWGBPSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- DECQYTKNYGKQJV-SJBAFXMYSA-N CC(=O)c1cc(F)c2nc(N3C4CC[C@H]3C[C@@H](OCc3c(-c5ccccc5OC(F)(F)F)noc3C3CC3)C4)sc2c1 Chemical compound CC(=O)c1cc(F)c2nc(N3C4CC[C@H]3C[C@@H](OCc3c(-c5ccccc5OC(F)(F)F)noc3C3CC3)C4)sc2c1 DECQYTKNYGKQJV-SJBAFXMYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 241000218459 Carteria Species 0.000 description 1
- 101000709520 Chlamydia trachomatis serovar L2 (strain 434/Bu / ATCC VR-902B) Atypical response regulator protein ChxR Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- MEHUJCGAYMDLEL-UHFFFAOYSA-N Ethyl-triacetylaleuritat Natural products OCCCCCCC(O)C(O)CCCCCCCC(O)=O MEHUJCGAYMDLEL-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 108010079943 Pentagastrin Proteins 0.000 description 1
- 238000003332 Raman imaging Methods 0.000 description 1
- WSASFFHWOQGSER-UHFFFAOYSA-N Shellolic acid Natural products C1C23C(C(O)=O)CCC2C(C)(CO)C1C(C(O)=O)=CC3O WSASFFHWOQGSER-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000713 anti-steatotic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000012550 audit Methods 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000010405 clearance mechanism Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000006900 dealkylation reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 230000023611 glucuronidation Effects 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- OXVFDZYQLGRLCD-UHFFFAOYSA-N hydroxypioglitazone Chemical compound N1=CC(C(O)C)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 OXVFDZYQLGRLCD-UHFFFAOYSA-N 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000003818 metabolic dysfunction Effects 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- IWVKTOUOPHGZRX-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.COC(=O)C(C)=C IWVKTOUOPHGZRX-UHFFFAOYSA-N 0.000 description 1
- YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 1
- 229920003087 methylethyl cellulose Polymers 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- ZXERDUOLZKYMJM-ZWECCWDJSA-N obeticholic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)CCC(O)=O)CC[C@H]21 ZXERDUOLZKYMJM-ZWECCWDJSA-N 0.000 description 1
- 229960001601 obeticholic acid Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 229960000444 pentagastrin Drugs 0.000 description 1
- ANRIQLNBZQLTFV-DZUOILHNSA-N pentagastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1[C]2C=CC=CC2=NC=1)NC(=O)CCNC(=O)OC(C)(C)C)CCSC)C(N)=O)C1=CC=CC=C1 ANRIQLNBZQLTFV-DZUOILHNSA-N 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940026235 propylene glycol monolaurate Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000009490 roller compaction Methods 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 238000001757 thermogravimetry curve Methods 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229940070126 tropifexor Drugs 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Definitions
- the present invention relates to the field of pharmacy, particularly to a pharmaceutical composition for oral administration comprising particles, wherein said particles comprise an inert substrate, a mixture comprising a non-bile acid farnesoid X receptor (FXR) agonist, such as 2-[(1R,3r,5S)-3-( ⁇ 5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl ⁇ methoxy)-8-azabicyclo [3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one binder.
- FXR farnesoid X receptor
- the present invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising a non-bile acid farnesoid X receptor (FXR) agonist, such as 2-[(1R,3r,5S)-3-( ⁇ 5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl ⁇ methoxy)-8-azabicyclo [3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid or a pharmaceutically acceptable salt thereof, and another active pharmaceutical ingredient.
- FXR farnesoid X receptor
- the present invention also relates to a process for preparing said pharmaceutical composition for oral administration; and to the use of said pharmaceutical composition in the manufacture of a medicament.
- Nuclear receptors constitute a superfamily of transcriptional regulatory proteins that share structural and functional properties and function as receptors for example steroids, retinoids, vitamin D, and thyroid hormones (Evans et al. Science 1988, 240, 889).
- the farnesoid X receptor (FXR) is a member of the nuclear hormone receptor superfamily and is primarily expressed in the liver, kidney and intestine (Seol et al. Mol. Endocrinol. 1995, 9, 72-85; Forman et al. Cell 1995, 81, 687-693). It functions as a heterodimer with the retinoid X receptor (RXR) and binds to response elements in the promoters of target genes to regulate gene transcription.
- the FXR-RXR heterodimer binds with highest affinity to an inverted repeat-1 (IR-1) response element, in which consensus receptor-binding hexamers are separated by one nucleotide.
- FXR is part of an interrelated process, in that FXR is activated by bile acids (the end product of cholesterol metabolism) (Makishima et al. Science 1999, 284, 1362-1365; Parks et al. Science 1999, 284, 1365-1368; Wang et al. Mol. Cell. 1999, 3, 543-553), which serve to inhibit cholesterol catabolism (Urizar et al. J. Biol. Chem. 2000, 275, 39313-39317).
- FXR agonists have been explored as therapeutics against non-alcoholic steatohepatitis (NASH).
- the present invention also relates to:
- Example 1 The compound was disclosed for the first time in WO 2012/087519 (Example 1, compound 1-IB of the table on page 125) and it is also known under the name LJN452 and under its International Nonproprietary Name (INN) “Tropifexor”. Said compound may be used for the treatment of an FXR mediated disease or disorder.
- INN International Nonproprietary Name
- GLP-1RAs glucagon-like peptide 1 receptor agonists
- DPP4 dipeptidyl peptidase-4
- PPARs peroxisome proliferator-activated receptor
- ACC acetyl-CoA carboxylase
- TR ⁇ thyroid hormone receptor ⁇
- KHK ketohexokinase
- DGAT2 diacylglycerol Acyltransferase 2
- SGLT sodium-glucose linked transporter
- anti-inflammatory agents such as chemokine receptor 2/5 (CCR2/5) antagonists
- anti-fibrosis agents such as Galectin-3 inhibitors and Lysyl oxidase-like 2 (LOXL 2) inhibitors.
- NAFLD and NASH are complex and multiple redundant pathways may be implicated, there is a need to provide treatments for nonalcoholic fatty liver disease (NAFLD), NASH and fibrotic/cirrhotic that can address the different aspects of these complex conditions, while demonstrating an acceptable safety and/or tolerability profile.
- NAFLD nonalcoholic fatty liver disease
- NASH fibrotic/cirrhotic
- FIG. 1 shows the dissolution profile for Capsule (C1) comprising 0.03 mg Compound (A), as disclosed herein, (500 mL and 900 mL vessels volume).
- FIG. 2 shows the dissolution profile for Capsule (C2) comprising 0.16 mg Compound (A) (900 mL vessels volume).
- FIG. 3 shows the dissolution profile for tablets comprising Formulation 5 (F5) and Formulation 6 (F6) with 0.03 mg of Compound (A), as disclosed herein, compressed at lowest and highest compression forces relative to the dry blend capsule formulation (0.1 mg release profile).
- FIG. 4 shows the dissolution profile for tablets comprising Formulation 5 (F5) and Formulation 6 (F6) with 0.03 mg of Compound (A), as disclosed herein, compressed at lowest and highest compression forces relative to the dry blend capsule formulation (0.1 mg release profile).
- FIG. 5 shows the XRPD diffractograms of the lactose, the common blend of Formulation 6 (F6) and the seal coated Formulation 2 (F2s).
- FIG. 6 shows the DSC thermograms obtained for the seal coated Formulation 2 (F2s).
- FIG. 7 shows the particle size distribution (PSP) of the seal coated Formulation 2 (F2s).
- FIG. 8 shows the particle size distribution (PSP) of the tablet blend of Formulation 6 (F6) of the sealed coated tablet formulation comprising Compound (A).
- FIG. 9 shows the SEM analysis of Lactose (inert substrate without Compound (A)) at 5 ⁇ m.
- FIG. 10 shows the SEM analysis of the Formulation 2 (F2) at 5 ⁇ m.
- FIG. 11 shows the SEM analysis of the Formulation 2 (F2) at 100 ⁇ m
- FIG. 12 shows the SEM analysis of the seal coated Formulation 2 (F2s) at 100 ⁇ m.
- FIG. 13 shows the SEM analysis of the Formulation 2 (F2s) at 20 ⁇ m.
- FIG. 14 shows the SEM analysis of the sealed coated Formulation 2 (F2s) at 20 ⁇ m.
- FIG. 15 shows the surface Raman mapping of the sealed coated Formulation 2 (F2s) at 10 ⁇ m resolution.
- FIG. 16 shows the surface Raman mapping of sealed coated Formulation 2 (F2s) at 20 ⁇ m resolution.
- FIG. 17 shows the Raman Spectra comparing crystalline and amorphous Compound (A), with Compound (A) in the Formulation 2 (F2) (0-1777 cm ⁇ 1 range).
- FIG. 18 shows the average plasma concentration over time for Compound (A) in different formulations in the dog.
- This non-bile acid FXR agonist is a highly potent active pharmaceutical ingredient (API) classified by the biopharmaceutical classification system as a class IV compound, e.g. poorly soluble and poorly permeable compound.
- API active pharmaceutical ingredient
- this non-bile acid FXR agonist is difficult to formulate due to its physicochemical properties and its high potency. Finding a suitable pharmaceutical composition, in a reliable and robust way, proved challenging. For example, due to its very high potency a low dosage is needed (sub-milligrams or micrograms), generating unwanted formulation issues such as content uniformity, and additional manufacturing difficulties, particularly when practiced on a larger manufacturing scale.
- this non-bile acid FXR agonist has a low water solubility and mixing the compound with conventional excipients to provide an effective composition proved difficult (owing to instability of the formulation, unpredictable dissolution rates and variable bioavailability). Accordingly, a suitable and robust solid pharmaceutical composition overcoming the above problems needs to be developed.
- the present invention relates to a pharmaceutical composition for oral administration comprising (a) an inert substrate, and (b) a mixture comprising 2-[(1R,3r,5S)-3-( ⁇ 5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl ⁇ methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one binder.
- the present invention relates to a pharmaceutical composition for oral administration comprising particles, wherein said particles comprise (a) an inert substrate, and (b) a mixture comprising 2-[(1R,3r,5S)-3-( ⁇ 5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl ⁇ methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one binder.
- a pharmaceutical composition for oral administration comprising particles, wherein said particles comprise (a) an inert substrate, and (b) a mixture comprising 2-[(1R,3r,5S)-3-( ⁇ 5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl ⁇ methoxy)-8-aza bicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one binder.
- Item A2 The pharmaceutical composition according to item A1, wherein 2-[(1R,3r,5S)-3-( ⁇ 5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl ⁇ methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, is in amorphous form, crystalline form, or a mixture thereof.
- Item A3 The pharmaceutical composition according to item A1 to A2, wherein 2-[(1R,3r,5S)-3-( ⁇ 5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl ⁇ methoxy)-8-azabicyclo[3.2.1] octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid is a free form.
- Item A4 The pharmaceutical composition according to items A1 to A3, wherein the (b) mixture comprising 2-[(1R,3r,5S)-3-( ⁇ 5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl ⁇ methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one binder, is dispersed onto the (a) inert substrate.
- the (b) mixture comprising 2-[(1R,3r,5S)-3-( ⁇ 5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl ⁇ methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid
- Item A5 The pharmaceutical composition according to items A1 to A3, wherein the (a) inert substrate is coated with the (b) mixture comprising 2-[(1R,3r,5S)-3-( ⁇ 5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl ⁇ methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one binder.
- Item A6 The pharmaceutical composition according to any one of items A1 to A5, wherein the (a) inert substrate comprises a material which is selected from the group consisting of lactose, microcrystalline cellulose, mannitol, sucrose, starch, granulated hydrophilic fumed silica, or mixtures thereof.
- the (a) inert substrate comprises a material which is selected from the group consisting of lactose, microcrystalline cellulose, mannitol, sucrose, starch, granulated hydrophilic fumed silica, or mixtures thereof.
- Item A7 The pharmaceutical composition according to any one of items A1 to A6, wherein the binder is selected from the group consisting of polyvinyl pyrrolidone, hydroxypropyl cellulose, hypromellose, carboxymethyl cellulose, methyl cellulose, hydroxyethyl cellulose, carboxyethyl cellulose, carboxymethylhydroxyethyl cellulose, polyethylene glycol, polyvinylalcohol, shellac, polyvinyl alcohol-polyethylene glycol co-polymer, or a mixtures thereof.
- Item A8 The pharmaceutical composition according to any one of items A1 to A7, wherein the particles further comprises an outer (c) seal coating layer.
- Item A9 The pharmaceutical composition according to any one of items A1 to A8, wherein the outer (c) seal coating layer is selected from the group consisting of hydroxypropyl methyl cellulose, polyvinyl pyrrolidone, hydroxypropyl cellulose, carboxymethyl cellulose, methyl cellulose, hydroxyethyl cellulose, carboxyethyl cellulose, carboxymethylhydroxyethyl cellulose, polyethylene glycol, polyvinylalcohol, or mixtures thereof.
- Item A10 The pharmaceutical composition according to any one of items A1 to A9, wherein the particles are further formulated into a final dosage form, optionally in the presence of at least one pharmaceutically acceptable excipient, and wherein said final dosage form is a capsule, a tablet, a mini-tablet, a sachet, or a stickpack.
- Item A11 The pharmaceutical composition according to item A10, wherein the final dosage form is a capsule or a tablet.
- Item A12 The pharmaceutical composition according to any one of items A1 to A11, comprising at least one further active pharmaceutical ingredient.
- Item A13 The pharmaceutical composition according to any one of items A1 to A12, wherein the final dosage form comprises 2-[(1R,3r,5S)-3-( ⁇ 5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl ⁇ methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, in an amount of about 0.01 mg to about 2 mg.
- Item A14 A process for preparing the pharmaceutical composition for oral administration, as defined in items A1 to A13, said process comprising the steps of:
- Item A15 The process according to item A14, wherein the at least one protic polar solvent is selected from the group consisting of organic solvents, water, or mixtures thereof.
- Item A16 The process according to item A15, wherein the organic solvent is selected from the group consisting of methanol, ethanol, isopropanol, n-propanol, n-butanol, or mixtures thereof.
- Item A18 The process according to items A14 to A17, wherein the solvent is removed at a temperature of 20° C. to 130° C.
- Item A20 The process according to any one of items A14 to A18, wherein the (a) inert substrate is coated with the mixture of step (i).
- Item A22 The process according to any one of items A14 to A21, comprising the step of further adding at least one additional active pharmaceutical ingredient.
- Items A23 The process according to any one of items A14 to A22, further comprising preparing the final dosage form by optionally mixing the particles with at least one pharmaceutically acceptable excipient.
- Items A24 The process according to any one of items A14 to A23, wherein the at least one pharmaceutically acceptable excipient is selected from the group consisting of lactose, mannitol, microcrystalline cellulose, dicalcium phosphate, polyvinyl pyrrolidone, hydroxypropyl methylcellulose, croscarmellose sodium, crospovidone, sodium starch glycolate, colloidal silicon dioxide, magnesium stearate, sodium stearyl fumarate, or mixtures thereof.
- the at least one pharmaceutically acceptable excipient is selected from the group consisting of lactose, mannitol, microcrystalline cellulose, dicalcium phosphate, polyvinyl pyrrolidone, hydroxypropyl methylcellulose, croscarmellose sodium, crospovidone, sodium starch glycolate, colloidal silicon dioxide, magnesium stearate, sodium stearyl fumarate, or mixtures thereof.
- Item A25 The process according to any one of items A14 to A24, wherein the final dosage form is encapsulated or tableted.
- Item A26 A process for preparing a suspension comprising mixing the (b) mixture comprising 2-[(1R,3r,5S)-3-( ⁇ 5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl ⁇ methoxy-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one binder, with water.
- Item A27 A process for preparing a dispersible solution comprising mixing the (b) mixture comprising 2-[(1R,3r,5S)-3-( ⁇ 5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl ⁇ methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one binder, with an organic solvent.
- Item A28 A solid dispersion comprising 2-[(1R,3r,5S)-3-( ⁇ 5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl ⁇ methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one binder.
- Item A29 A dispersible solution comprising 2-[(1R,3r,5S)-3-( ⁇ 5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl ⁇ methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, in an organic solvent.
- Item A30 The pharmaceutical composition according to any one of items A1 to A13, for use as a medicine.
- Item A31 The pharmaceutical composition according to any one of items A1 to A13, for use in the treatment of cholestasis, intrahepatic cholestatis, estrogen-induced cholestasis, drug-induced cholestasis, cholestasis of pregnancy, parenteral nutrition-associated cholestasis, primary biliary cirrhosis (PBC), non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver cirrhosis, alcohol-induced cirrhosis, cystic fibrosis, or liver fibrosis, preferably for primary biliary cirrhosis (PBS) or non-alcoholic steatohepatitis (NASH).
- PBC primary biliary cirrhosis
- NAFLD non-alcoholic fatty liver disease
- NASH non-alcoholic steatohepatitis
- liver cirrhosis alcohol-induced cirrhosis
- cystic fibrosis or
- Item A32 Use of the pharmaceutical composition for oral administration as defined in items A1 to A13, for the manufacture of a medicament for cholestasis, intrahepatic cholestatis, estrogen-induced cholestasis, drug-induced cholestasis, cholestasis of pregnancy, parenteral nutrition-associated cholestasis, primary biliary cirrhosis (PBC), non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver cirrhosis, alcohol-induced cirrhosis, cystic fibrosis, or liver fibrosis, preferably for primary biliary cirrhosis (PBS) or non-alcoholic steatohepatitis (NASH).
- PBC primary biliary cirrhosis
- NAFLD non-alcoholic fatty liver disease
- NASH non-alcoholic steatohepatitis
- liver cirrhosis alcohol-induced cirrhosis, cystic
- a pharmaceutical composition for oral administration comprising (a) an inert substrate, and (b) a mixture comprising 2-[(1R,3r,5S)-3-( ⁇ 5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl ⁇ methoxy)-8-aza bicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one binder.
- Item A34 The pharmaceutical composition according to any one of items A1 to A13, and A33, wherein the inert substrate is present in an amount from about 16-fold w/w to about 6400-fold w/w, from about 100-fold w/w to about 3200-fold w/w, from about 400-fold w/w to about 1600-fold w/w, from about 800-fold w/w to about 1200-fold w/w, from about 900-fold w/w to about 1000-fold w/w based on an amount of the 2-[(1R,3r,5S)-3-( ⁇ 5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl ⁇ methoxy)-8-aza bicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof.
- Item A35 The pharmaceutical composition according to any one of items A1 to A13, A33, and A34, wherein the inert substrate is present in an amount about 100-fold w/w, about 300-fold w/w, about 500-fold w/w, about 600-fold w/w, about 700-fold w/w, about 800-fold w/w, about 900-fold w/w, about 1000-fold, about 1200-fold w/w, about 1500-fold w/w based on an amount of the 2-[(1R,3r,5S)-3-( ⁇ 5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl ⁇ methoxy)-8-aza bicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof.
- Item A36 The pharmaceutical composition according to any one of items A1 to A13, A33 to A35, wherein the at least one binder in the (b) mixture is present in an amount from about 0.5-fold w/w to about 300-fold w/w, from about 1-fold to about 150 fold w/w, from about 10-fold w/w to 100-fold w/w, from 25-fold w/w to about 75-fold w/w, or from about 40-fold w/w to about 60-fold w/w based on an amount of the 2-[(1R,3r,5S)-3-( ⁇ 5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl ⁇ methoxy)-8-aza bicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof.
- Item A37 The pharmaceutical composition according to any one of items A1 to A13, A33 to A36, wherein the binder is polyvinyl pyrrolidone.
- Item A38 The pharmaceutical composition according to any one of items A1 to A13, A33 to A37, wherein the binder is present in an amount from about 10-fold w/w to about 100-fold w/w, or about 50-fold w/w based on an amount of the 2-[(1R,3r,5S)-3-( ⁇ 5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl ⁇ methoxy)-8-aza bicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof.
- Item A39 The pharmaceutical composition according to any one of items A1 to A13, A33 to A38, wherein 2-[(1R,3r,5S)-3-( ⁇ 5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl ⁇ methoxy)-8-aza bicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof is present in an amount from about 0.05% w/w to about 2.5% w/w, from about 0.07% w/w to about 2% w/w, from about 0.08% w/w to about 1% w/w, from about 0.09% w/w to about 0.5% w/w, or from about 0.1% w/w to about 0.25% w/w relative to a weight of the pharmaceutical composition.
- composition Comprising Compound A containing Compound A in low amounts provides Composition Comprising Compound A containing Compound A in low amounts.
- Composition Comprising Compound A is directly processed into final dosage forms.
- At least one further active pharmaceutical ingredient Compound (B) is combined with Compound A in a dosage form.
- Compound (B) is introduced via Composition Comprising Compound B.
- Compound B can be a solid, or a liquid.
- Composition Comprising Compound B can be a particle, a granule, a dispersion (solid or liquid), a tablet, a mini-tablet, a bead, a pellet, a solution, or a mixture thereof.
- Composition Comprising Compound B can be combined with Composition Comprising Compound A to form Composition Comprising Compounds A and B which is then processed into final dosage forms.
- composition Comprising Compound A
- a low dose non-bile acid FXR agonist such as 2-[(1R,3r,5S)-3-( ⁇ 5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl ⁇ methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, (Compound (A), as disclosed herein), proved difficult. For example, difficulties in weighing the low amount of non-bile acid FXR agonist, content uniformity, formulation, dissolution rate and bioavailability issues were observed. Ultimately, those issues were affecting the manufacturing process and in vivo performance of the pharmaceutical composition.
- a pharmaceutical composition for oral administration comprising (a) an inert substrate, and (b) a mixture comprising a non-bile acid FXR agonist, and at least one binder.
- the non-bile acid FXR agonist is 2-[(1R,3r,5S)-3-( ⁇ 5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl ⁇ methoxy)-8-azabicyclo [3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof (Compound (A)).
- the pharmaceutical composition for oral administration of the present invention is a particle.
- the present invention provides a pharmaceutical composition for oral administration comprising particles, wherein said particles comprise (a) an inert substrate, and (b) a mixture comprising Compound (A) (2-[(1R,3r,5S)-3-( ⁇ 5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl ⁇ methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof), and at least one binder.
- Compound (A) (2-[(1R,3r,5S)-3-( ⁇ 5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl ⁇ methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-
- Compound (A) can also be present in its free form.
- the Compound (A), as described herein, may also be present in a crystalline form, in an amorphous form, or a mixture thereof.
- the present invention also provides a pharmaceutical composition for oral administration comprising (a) an inert substrate, and (b) a mixture comprising a non-bile acid FXR agonist, and at least one binder.
- the non-bile acid FXR agonist is 2-[(1R,3r,5S)-3-( ⁇ 5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl ⁇ methoxy)-8-azabicyclo [3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof (Compound (A)).
- the pharmaceutical composition comprises an (a) inert substrate on which the (b) mixture comprising Compound (A), and at least one binder, is added.
- the (a) inert substrate comprises a material that does not chemically react to the (b) mixture comprising Compound (A), and at least one binder.
- the (a) inert substance is, for example, a pharmaceutically acceptable excipient known in the art not to interact chemically or physically with the active substance.
- the (a) inert substrate can also be coated with a layer to protect the (a) inert substrate from any unwanted chemical or physical interaction that may happen during the formulation process.
- the (a) inert substrate can also be treated with an acceptable excipient (for example, a binder) to render certain desirable process qualities, such as particle size and flowability, to the inert substance.
- the (a) inert substrate may comprise a material, which is selected from the group consisting of lactose, microcrystalline cellulose, mannitol, sucrose, starch, granulated hydrophilic fumed silica, tartaric acid, or mixtures thereof.
- the material may comprise a material selected from the group consisting of lactose, microcrystalline cellulose, mannitol, sucrose, starch, granulated hydrophilic fumed silica, or mixtures thereof.
- the material is lactose, or mannitol.
- the inert substrate can be present in an amount from about 16-fold w/w to about 6400-fold w/w, from about 100-fold w/w to about 3200-fold w/w, from about 400-fold w/w to about 1600-fold w/w, from about 800-fold w/w to about 1200-fold w/w, from about 900-fold w/w to about 1000-fold w/w based on the amount of Compound (A).
- the inert substrate is present in an amount about 100-fold w/w, about 300-fold w/w, about 500-fold w/w, about 600-fold w/w, about 700-fold w/w, about 800-fold w/w, about 900-fold w/w, about 1000-fold, about 1200-fold w/w, about 1500-fold w/w based on the amount of Compound (A) or a pharmaceutically acceptable salt thereof.
- Suitable binders for the (a) inert substance or the (b) mixture can be selected, for example, but not limited to, from the group consisting of cellulose acetate, cellulose fatty acid ester, cellulose nitrates (e.g. nitrocelluloses, nitrowools, Collodion), cellulose ether, ethyl cellulose, carboxymethyl cellulose (e.g. sodium cellulose gum, cellulose gum), methyl cellulose (e.g.
- cellulose methyl ether, Tylose methylethyl cellulose, methylhydroxypropyl cellulose, polyvinyl pyrrolidone, hydroxypropyl cellulose, hypromellose (HPMC), hydroxyethyl cellulose, carboxyethyl cellulose, carboxymethyl hydroxyethyl cellulose, polyethylene glycol, polyvinyl alcohol, shellac, polyvinyl alcohol-polyethylene glycol co-polymer, or mixtures thereof.
- the binder is selected from the group consisting of polyvinyl pyrrolidone, hydroxypropyl cellulose, hypromellose, carboxymethyl cellulose, methyl cellulose, hydroxyethyl cellulose, carboxyethyl cellulose, carboxymethyl hydroxyethyl cellulose, polyethylene glycol, polyvinylalcohol, shellac, polyvinyl alcohol-polyethylene glycol co-polymer, or mixtures thereof. More preferably, the binder is polyvinyl pyrrolidone (PVP).
- PVP polyvinyl pyrrolidone
- the at least one binder present in the (b) mixture can be present in an amount from about 0.5-fold w/w to about 300-fold w/w, from about 1-fold to about 150 fold, from about 10-fold w/w to 100-fold w/w, from 25-fold w/w to about 75-fold w/w, or from about 40-fold w/w to about 60-fold w/w based on the amount of Compound (A), or a pharmaceutically acceptable salt thereof.
- the binder is polyvinyl pyrrolidone.
- the binder is present in an amount from about 10-fold w/w to about 100-fold w/w, from about 25-fold w/w to about 75-fold w/w, or from about 40-fold w/w to about 60-fold w/w based on the amount of Compound (A). More preferably, the binder is present in an amount about 50-fold w/w based on the amount of Compound (A), or a pharmaceutically acceptable salt thereof.
- the (b) mixture comprising Compound (A), and at least one binder can be added onto the (a) inert core using different techniques known in the art.
- the (a) inert core can be sprayed or coated with the (b) mixture, using, for example, spray drying, spray layering, spray dispersing, spray coating, fluid bed drying, fluid bed coating, granulators with spray nozzles, or a combination of those spraying techniques thereof.
- the (b) mixture comprising Compound (A), and at least one binder is dispersed onto the (a) inert substrate.
- the (a) inert substrate is coated with the (b) mixture comprising Compound (A), and at least one binder.
- the (b) mixture comprising Compound (A), and at least one binder is preferably dispersed or coated onto the (a) inert core as discrete particles, thus, providing a large surface area for instant dissolution despite the poor solubility of the drug. As a result, a fast dissolution rate of Compound (A) can be achieved.
- the particle optionally further comprises an outer (c) seal coating layer.
- the outer (c) seal coating layer comprises a material that does not chemically react with the (b) mixture comprising Compound (A), and at least one binder, and protects the (b) mixture, as defined herein, from any unwanted chemical or physical interaction that may happen during the formulation process, e.g. with additives, pharmaceutically acceptable excipients, or any further active pharmaceutical ingredient.
- the outer (c) seal coating layer also provides an additional barrier for taste masking.
- the outer (c) seal coating layer can also provide a barrier for gastric or stomach release while allowing for enteric or intestinal release.
- the outer (c) seal coating layer comprises, for example, hydroxypropyl methyl cellulose (HPMC), magnesium stearate, polyvinyl pyrrolidone, hydroxypropyl cellulose, carboxymethyl cellulose, methyl cellulose, hydroxyethyl cellulose, carboxyethyl cellulose, carboxymethylhydroxyethyl cellulose, polyethylene glycol, polyvinylalcohol, cellulose acetate phthalates (CAP), cellulose acetate trimellitates (CAT), hydroxypropyl methyl cellulose phthalates (HPMCP), hydroxypropyl methyl cellulose acetate succinate (HPMCAS), polyvinyl acetate phthalate (PVAP), methyl methacrylate-methacrylic acid copolymers, cellulose acetate succinate, fatty acids, waxes, shellac, sodium alginate, zein, or mixtures thereof.
- HPMC hydroxypropyl methyl cellulose
- magnesium stearate polyvinyl
- the outer (c) seal coating layer comprises, for example, hydroxypropyl methyl cellulose, magnesium stearate, polyvinyl pyrrolidone, hydroxypropyl cellulose, carboxymethyl cellulose, methyl cellulose, hydroxyethyl cellulose, carboxyethyl cellulose, carboxymethylhydroxyethyl cellulose, polyethylene glycol, polyvinylalcohol, or mixtures thereof.
- the outer (c) seal coating layer comprises magnesium stearate, hydroxypropyl methyl cellulose, or mixtures thereof. More preferably, the material used for the outer (c) seal coating layer is hydroxypropyl methyl cellulose (HPMC).
- the material used for the outer (c) seal coating layer can be present in an amount of about 0.5% w/w to about 6% w/w based on the total weight of the particles. Preferably, in an amount of 1% w/w to about 5% w/w based on the total weight of the particles. More preferably, in an amount of about 3% w/w based on the total weight of the particles.
- the above-mentioned ranges apply to all outer (c) seal coating layer materials as listed above.
- the size of the particle corresponds to the size of the (a) inert substrate, as disclosed herein, together with the coating.
- the particle can have a size from about 20 ⁇ m to about 500 ⁇ m.
- the particle can have a size from about 50 ⁇ m to 400 ⁇ m.
- the particle can have a size of about 100 ⁇ m to about 300 ⁇ m.
- the particle size is measured, for example, by laser diffraction methodology (e.g. particle size distribution (PSD)).
- PSD particle size distribution
- the particle size is measured using the instrument and method disclosed herein.
- a further aspect of the present invention provides a process for preparing the pharmaceutical composition for oral administration, said process comprising the steps of:
- a further aspect of the present invention provides a process for preparing the pharmaceutical composition for oral administration, said process comprising the steps of:
- a further aspect of the present invention provides a process for preparing the pharmaceutical composition for oral administration comprising particles, as defined herein, said process comprising the steps of:
- the pharmaceutical composition can comprise particles comprising Compound (A), wherein compound (A) is present from about 0.05% w/w to about 2.5% w/w, from about 0.07% w/w to about 2% w/w, from about 0.08% w/w to about 1% w/w, from about 0.09% w/w to about 0.5% w/w, or from about 0.1% w/w to about 0.25% w/w of Compound (A) relative to the total dry weight of the pharmaceutical composition.
- compound (A) is present from about 0.05% to about 0.25%, or from about 0.08% to about 0.15% w/w relative to the total dry weight of the pharmaceutical composition.
- the at least one protic polar solvent comprises organic solvents, water, or mixtures thereof.
- Suitable, protic polar organic solvents can be selected from, for example, but not limited to, methanol, ethanol, isopropanol, n-propanol, n-butanol, sec-butanol, iso-butanol, tert-butanol, hexanol, nitromethane, or mixtures thereof.
- the organic solvent is selected from the group consisting of methanol, ethanol, isopropanol, n-propanol, n-butanol, or mixtures thereof. More preferably, the protic polar solvent is water, ethanol, or mixtures thereof.
- the organic solvent is ethanol.
- the optionally at least one polar protic solvent is evaporated at a temperature of about 20° C. to about 130° C.
- the at least one polar protic solvent is removed at a temperature of about 50° C. to about 110° C. More preferably, at a temperature of about 70° C. to about 100° C.
- Another aspect of the present invention relates to a process for preparing the pharmaceutical composition for oral administration comprising particles, as defined herein, said process comprising the steps of:
- Another aspect of the present invention relates to a process for preparing the pharmaceutical composition for oral administration comprising particles, as defined herein, said process comprising the steps of:
- Another aspect of the present invention relates to a process for preparing the pharmaceutical composition for oral administration, as defined herein, wherein the mixture of step (i) is dispersed onto the (a) inert substrate.
- Yet another aspect of the present invention relates to a process for preparing the pharmaceutical composition for oral administration, as defined herein, wherein the (a) inert substrate is coated with the mixture of step (i).
- a further aspect of the present invention relates to a process for preparing the pharmaceutical composition for oral administration, as defined herein, said process further comprising the step of adding an outer (c) seal coating layer onto said particles.
- the (c) seal coating layer prevents chemical-physical interactions between the particles and any other active or non-active substances that may be used in the preparation of the final dosage form.
- Another aspect of the present invention relates to the process for preparing the pharmaceutical composition for oral administration comprising particles, as defined herein, said process comprising, for example, the steps of:
- Another aspect the present invention provides for a process for preparing a dispersible solution comprising mixing the (b) mixture comprising 2-[(1R,3r,5S)-3-( ⁇ 5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl ⁇ methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one binder with an organic solvent, as defined herein.
- the organic solvent is ethanol.
- Another aspect the present invention relates to a dispersible solution comprising 2-[(1R,3r,5S)-3-( ⁇ 5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl ⁇ methoxy)-8-azabicyclo [3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one binder, in an organic solvent.
- Another aspect of the present invention relates to the process for preparing the pharmaceutical composition for oral administration comprising particles, as defined herein, said process comprising, for example, the steps of:
- Another aspect of the present invention provides for a process for preparing a suspension comprising mixing the (b) mixture comprising 2-[(1R,3r,5S)-3-( ⁇ 5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl ⁇ methoxy-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, at least one binder, with water, as defined herein.
- Another aspect of the present invention relates to a solid dispersion comprising 2-[(1R,3r,5S)-3-( ⁇ 5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl ⁇ methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one binder, in water, as defined herein.
- Another aspect of the present invention also provides for a process, as defined herein, comprising the step of further adding at least one additional active pharmaceutical ingredient.
- Another aspect of the present invention provides for a process further comprising preparing the final dosage form by mixing the particles with at least one pharmaceutically acceptable excipient.
- the at least one pharmaceutically acceptable excipient can be selected, for example, from the group consisting of lactose, mannitol, microcrystalline cellulose, dicalcium phosphate, polyvinyl pyrrolidone, hydroxypropyl methylcellulose, croscarmellose sodium, crospovidone, sodium starch glycolate, colloidal silicon dioxide, magnesium stearate, sodium stearyl fumarate, or mixtures thereof.
- the excipient can be selected from the group consisting of mannitol, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, or mixtures thereof.
- composition Comprising Compound A The pharmaceutical composition comprising Compound A either with or without a binder, an inert substrate, or other excipients is hereafter referred to as Composition Comprising Compound A.
- compound (A) or a pharmaceutically acceptable salt thereof is present from about 0.05% to about 2.5%, from about 0.07% to about 2%, from about 0.08% to about 1%, from about 0.09% to about 0.5%, or from about 0.1% to about 0.25% w/w relative to the total weight of Particles Comprising Compound A.
- compound (A) or a pharmaceutically acceptable salt thereof is present from about 0.05% to about 0.25%, or from about 0.08% to about 0.15% w/w relative to the total weight of Composition Comprising Compound A.
- composition Comprising Compound B
- composition such as a solid composition, comprising Compound B.
- the identity of Compound B is not particularly limited.
- Compound B itself is a combination of two or more active pharmaceutical ingredients.
- Compound B can be a solid or a liquid.
- Composition Comprising Compound B can be a particle, a granule, a dispersion (solid or liquid), a tablet, a mini-tablet, a bead, a pellet, a solution, or a mixture thereof.
- Compound B may be selected from the following classes of active pharmaceutical ingredients: glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1RAs), dipeptidyl peptidase-4 (DPP4) inhibitors, peroxisome proliferator-activated receptor (PPARs) agonists, acetyl-CoA carboxylase (ACC) inhibitors, thyroid hormone receptor ⁇ (TR ⁇ ) agonists, ketohexokinase (KHK) inhibitors, diacylglycerol Acyltransferase 2 (DGAT2) inhibitors, sodium-glucose linked transporter (SGLT) inhibitors, anti-inflammatory agents (such as chemokine receptor 2/5 (CCR2/5) antagonists), and anti-fibrosis agents (such as Galectin-3 inhibitors and Lysyl oxidase-like 2 (LOXL 2) inhibitors).
- GLP-1RAs glucagon-like peptide 1 receptor agonists
- DPP4 dipeptidyl peptida
- the composition can have one or more additional ingredients.
- additional ingredients for example one or more binders, one or more fillers, one or more disintegrants, or one or more lubricants.
- Further additional ingredients can also be present, although it should be understood that no particular additional ingredient is required.
- the one or more binders are discussed in the context of Composition Comprising Compound A above.
- the one or more fillers when used, can include at least one of lactose, microcrystalline cellulose, calcium phosphate dibasic anhydrous, calcium phosphate dibasic dihydrate, calcium phosphate tribasic, cellulose powder, magnesium carbonate, calcium sulfate, starch, talc, sucrose, dextrose, mannitol, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, carboxymethylcellulose, fructose, xylitol, sorbitol, and combinations thereof.
- the one or more disintegrants when used, can include at least one of cross-linked polyvinylpyrrolidone, cross-linked sodium carboxymethyl cellulose, and sodium starch glycolate.
- the one or more disintegrants can be cross-linked sodium carboxymethyl cellulose.
- the weight ratio of the one or more disintegrants, such as cross-linked sodium carboxymethyl cellulose, to Compound B is not particularly limited.
- the one or more disintegrants can be present in an amount of from about 2% to about 10%, such as about 4% to about 8%, or about 6%, by weight of the composition.
- the one or more lubricants when used, can include at least one of talc, silica, stearin, magnesium stearate, or stearic acid.
- the one or more lubricants can be magnesium stearate.
- the one or more lubricants can be present in an amount of from about 0.25% to about 5%, such as from about 0.75% to about 3%, or about 1.25%, by weight of the composition.
- composition Comprising Compound B (containing Compound B with or without other excipients) hereafter.
- composition Comprising Compounds A and B
- the current invention also provides a fixed dose combination containing Compounds A and B. As discussed above, the effective formulation of low doses of Compound A or a pharmaceutically acceptable salt thereof proved difficult.
- the current invention overcomes the difficulties in formulating a fixed dose combination composition containing both Compounds A and B by utilizing each of Composition Comprising Compound A and Composition Comprising Compound B as intermediates.
- the fixed dose combination composition prior to the conversion to a final dosage form is referred to as Composition Comprising Compounds A and B hereafter.
- the current invention provides compatible Composition Comprising Compound A and Composition Comprising Compound B.
- the free combination of the two allows Compound A and Compound B in a desired proportion according to the desired pharmaceutical and/or therapeutic effects.
- the compatibility allows ready preparation of unit dosage forms, or multiple-dosage forms from Composition Comprising Compounds A and B.
- Composition Comprising Compound A and Composition Comprising Compound B are combined (e.g. mixed or blended) in a proportion for a desired therapeutic effect.
- One or more of the binders, fillers, disintegrants, lubricants, and other additional ingredients discussed above can also be admixed in the combining process.
- the method of combining is not particularly limited.
- composition comprising Composition Comprising Compound (A) may be directly converted into final dosage forms.
- Composition Comprising Compound (A) may also be combined with Composition Comprising Compound B to form Composition Comprising Compounds A and B which then is processed into final dosage forms.
- Another aspect the present invention provides for a process, as defined herein, wherein the final dosage form is encapsulated or tableted.
- the pharmaceutical composition is intended to be administered orally to humans and animals in unit dosage forms, or multiple-dosage forms, such as, for example, a capsule, a caplet, a powder, pellets, granules, a tablet, a mini-tablet, a sachet, a pouch, or a stick pack.
- the pharmaceutical composition may contain Compound (A) or also with Compound (B) as described above.
- the unit dosage form, or multi-dosage form for example, is a capsule, a tablet, a mini-tablet, a sachet, a pouch, or a stick pack. More preferably, the pharmaceutical composition is in the form of a capsule, or a tablet. This can be achieved by mixing the pharmaceutical composition, as defined herein, with diluents, lubricants, binders, disintegrants, and/or absorbents, colorants, flavours and sweeteners.
- Capsules comprising the particles or the compositions of the invention, as defined herein, can be prepared using techniques known in the art. Suitable capsules can be selected from a soft gelatin capsule, a hard shell capsule, a hard gelatin capsule, a plant-based shell capsule, a hypromellose (HPMC) based capsule, or mixtures thereof.
- the pharmaceutical composition, as described herein, can be presented in a hard gelatin capsule, a soft gelatin capsule, a hard shell capsule, or a hard plant shell capsule, hypromellose (HPMC) capsule wherein the pharmaceutical composition is further mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate, or cellulose-based excipient.
- an inert solid diluent for example, calcium carbonate, calcium phosphate, or cellulose-based excipient.
- the hard gelatin capsules are made of two-piece outer gelatin shells referred to as the body and the cap.
- the shell may comprise vegetal or animal gelatin (e.g. pork, beef, or fish based gelatin), water, one or more plasticizers, and possibly some preservatives.
- the capsule may hold a dry mixture, in the form of a powder, very small pellets, or particles, comprising a non-bile acid FXR agonist, such as Compound (A), at least one binder, and optionally excipients.
- the shell may be transparent, opaque, coloured, or flavoured.
- the capsules containing the particles can be coated by techniques well known in the art with enteric- and/or gastric-resistant or delayed-release coating materials, to achieve, for example, greater stability in the gastrointestinal tract, or to achieve the desired rate of release.
- Hard gelatin capsules of any size e.g. size 000 to 5 can be prepared.
- Tablet comprising the particles of the invention, as defined herein, can be prepared using techniques known in the art. Suitable tablets may contain the particles in admixture with non-toxic pharmaceutical, which are suitable for the manufacture of tablets.
- excipients are, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose (e.g. lactose SD), mannitol (e.g. mannitol DC), magnesium carbonate, kaolin, cellulose (e.g.
- microcrystalline cellulose, powdered cellulose), calcium phosphate, or sodium phosphate granulating and disintegrating agents, for example, croscarmellose sodium, crospovidone, sodium starch glycolate, corn starch, or alginic acid; gliding agents, for example, fumed silica (e.g. Aerosil®, Aeroperl®); binding agents (e.g. for example, methyl cellulose, carboxymethyl cellulose, polyvinyl pyrrolidone, starch, gelatin, or acacia); and lubricating agents, for example magnesium stearate, sodium stearyl fumarate, stearic acid or talc.
- granulating and disintegrating agents for example, croscarmellose sodium, crospovidone, sodium starch glycolate, corn starch, or alginic acid
- gliding agents for example, fumed silica (e.g. Aerosil®, Aeroperl®)
- binding agents e.g. for
- the mixture of the particles in admixture with non-toxic pharmaceutical can be mixed using numerous known methods, such as, for example, mixing in a free-ball, or tumble blending.
- the mixture of the particles in admixture with non-toxic pharmaceutical can be compressed into a tablet using tableting techniques known in the art, such as, for example, a single punch press, a double punch press, a rotary tablet press, or a compaction on a roller compaction equipment.
- the compression force applied to form the tablet can be any suitable compression force that allows obtaining a tablet, for example, the compression applied can be between 0.5 to 50 kN, preferably between 1 to 30 kN.
- the tablets can be uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- tablets can be coated with a suitable polymer or a conventional coating material to achieve, for example, greater stability in the gastrointestinal tract, or to achieve the desired rate of release, for example the tablet can be coated with hypromellose (HPMC), magnesium stearate, polyethylene glycol (PEG), polyvinyl alcohol (PVA), Opadry®, Opadry II®, or mixtures thereof.
- HPMC hypromellose
- PEG polyethylene glycol
- PVA polyvinyl alcohol
- Opadry® Opadry II®
- a time delay material such as glyceryl monostearate or glyceryl distearate can be employed. Tablets of any shape or size can be prepared, and they can be opaque, coloured, or flavoured.
- the inert substrate such as lactose or mannitol
- the pre-treatment may employ an adequate binder, for example, HPMC and polyvinylpyrrolidone.
- the pre-treatment granulation can be a dry or wet process.
- the API such as Compound A is then layered onto the pre-treated inert substrate as described above.
- the non-bile acid FXR agonist such as Compound (A), alone or in combination with a second active pharmaceutical ingredient, as disclosed herein, are present in the pharmaceutical composition in an amount sufficient to exert a therapeutically useful effect in the absence of undesirable side effects on the patient treated. Due to the high potency of Compound (A), a low dose is preferable.
- Each unit dose contains a predetermined amount of the Compound (A), sufficient to produce the desired therapeutic effect.
- Each unit dose as disclosed herein, are suitable for human and animal subjects, are packaged individually and may be administered in fractions or multiples thereof.
- a multiple-dose form is a plurality of identical unit-dosage forms packaged in a single container to be administered in segregated unit-dose form. Examples of multiple-dose forms include vials, blisters, or bottles.
- Compound (A) or its pharmaceutically acceptable salt may be present in the pharmaceutical composition for oral administration in a low amount.
- the final dosage form comprises Compound (A) or its pharmaceutically acceptable salt, in an amount of about 0.01 mg to about 2 mg, about 0.03 mg to about 1.5 mg, about 0.05 mg to about 1 mg, or about 0.07 mg to about 0.09 mg.
- the low amount of the non-bile acid FXR agonist is about 0.01 mg, or about 0.02 mg, or about 0.03 mg, or about 0.04 mg, or about 0.05 mg, or about 0.06 mg, or about 0.07 mg, or about 0.08 mg, or about 0.09 mg, or about 0.1 mg, or about 0.12 mg, or about 0.14 mg, or about 0.15 mg, or about 0.2 mg, or about 0.25 mg, or about 0.5 mg, or about 0.8 mg, or about 1 mg, or about 1.2 mg, or about 1.4 mg, or about 1.5 mg, or about 1.8 mg, or about 2 mg.
- the amount is about 0.01 mg, or is about 0.03 mg, or is about 0.09 mg, or is about 0.1 mg, or is about 0.12 mg, or is about 0.14 mg, or is about 0.25 mg, or is about 0.5 mg, or is about 1 mg, or is about 1.5 mg, or the amount is about 2 mg. More preferably, the amount is about 0.01 mg, or is about 0.03 mg, or is about 0.09 mg, or is about 0.1 mg, or is about 0.5 mg, or the amount is about 2 mg.
- a further aspect of the invention relates to a pharmaceutical composition for oral administration, as defined herein, comprising at least one further active pharmaceutical ingredient Compound (B) in a therapeutically effective amount.
- the pharmaceutical composition for oral administration is useful, for example, as medicine, for the treatment of an FXR mediated condition or disorder such as, for example, cholestasis, intrahepatic cholestatis, estrogen-induced cholestasis, drug-induced cholestasis, cholestasis of pregnancy, parenteral nutrition-associated cholestasis, primary biliary cirrhosis (PBC), non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver cirrhosis, alcohol-induced cirrhosis, cystic fibrosis, or liver fibrosis.
- PBC primary biliary cirrhosis
- NAFLD non-alcoholic fatty liver disease
- NASH non-alcoholic steatohepatitis
- liver cirrhosis alcohol-induced cirrhosis, cystic fibrosis, or liver fibrosis
- the present disclosure provides the use of said pharmaceutical composition in the treatment of primary bil
- the final dosage form for oral administration is useful, for example, as medicine, for the treatment of an FXR mediated condition or disorder such as, for example, cholestasis, intrahepatic cholestatis, estrogen-induced cholestasis, drug-induced cholestasis, cholestasis of pregnancy, parenteral nutrition-associated cholestasis, primary biliary cirrhosis (PBC), non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver cirrhosis, alcohol-induced cirrhosis, cystic fibrosis, or liver fibrosis.
- PBC primary biliary cirrhosis
- NAFLD non-alcoholic fatty liver disease
- NASH non-alcoholic steatohepatitis
- liver cirrhosis alcohol-induced cirrhosis, cystic fibrosis, or liver fibrosis
- the present disclosure provides the use of said pharmaceutical composition in the treatment of primary
- Another aspect of the invention also provides for the use of the pharmaceutical composition, as disclosed herein, for the manufacture of a medicament for cholestasis, intrahepatic cholestatis, estrogen-induced cholestasis, drug-induced cholestasis, cholestasis of pregnancy, parenteral nutrition-associated cholestasis, primary biliary cirrhosis (PBC), non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver cirrhosis, alcohol-induced cirrhosis, cystic fibrosis, or liver fibrosis, preferably for primary biliary cirrhosis (PBS), or non-alcoholic steatohepatitis (NASH).
- PBC primary biliary cirrhosis
- NAFLD non-alcoholic fatty liver disease
- NASH non-alcoholic steatohepatitis
- liver cirrhosis alcohol-induced cirrhosis, cystic fibros
- Another aspect of the invention also provides for a method of treating a disease or disorder in a patient in need thereof, wherein the disease or disorder is cholestasis, intrahepatic cholestatis, estrogen-induced cholestasis, drug-induced cholestasis, cholestasis of pregnancy, parenteral nutrition-associated cholestasis, primary biliary cirrhosis (PBC), non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver cirrhosis, alcohol-induced cirrhosis, cystic fibrosis, or liver fibrosis, comprising the step of administering to the patient an effective amount of the pharmaceutical composition or the final dosage form.
- PBC primary biliary cirrhosis
- NAFLD non-alcoholic fatty liver disease
- NASH non-alcoholic steatohepatitis
- liver cirrhosis alcohol-induced cirrhosis, cystic fibrosis, or liver
- farsenoid X receptor refers to all mammalian forms of such receptors including, for example, alternative splice isoforms and naturally occurring isoforms (Huber et al. Gene, 2002, 290, 35).
- Representative farsenoid X receptor species include, without limitation, the rat (GenBank Accession No. NM_021745), the mouse (GenBank Accession No. NM_009108), and the human (GenBank Accession No. NM_005123) forms of the receptor.
- non-bile acid FXR agonist refers to an agent that directly binds to and upregulates the activity of non-bile acid FXRs.
- agonist refers to an agent that triggers at least one response by binding a non-endogenous ligand to the receptor.
- the agonist may act directly or indirectly with a second agent that itself modulates the activity of the receptor.
- the agonist may also act indirectly by modulating the activity of one or more agent(s) that modulate the amount of FXR mRNA or FXR protein in certain cells of a patient.
- pharmaceutically acceptable salts refers to salts that can be formed, for example, as acid addition salts, preferably with organic or inorganic acids. For isolation or purification purposes it is also possible to use pharmaceutically unacceptable salts, for example picrates or perchlorates. For therapeutic use, only pharmaceutically acceptable salts or free compounds are employed (where applicable in the form of pharmaceutical preparations), and these are therefore preferred.
- pharmaceutically acceptable refers to those compounds, materials, compositions, and/or dosage forms which are suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, other problem or complication, commensurate with a reasonable benefit/risk ratio.
- treat refers to ameliorating the disease or disorder (e.g. slowing, arresting or reducing the development of the disease, or at least one of the clinical symptoms thereof), to preventing, or delaying the onset, or development, or progression of the disease or disorder.
- those terms refer to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient and also to modulating the disease or disorder, either physically (e.g. stabilization of a discernible symptom), physiologically (e.g. stabilization of a physical parameter), or both.
- composition or “formulation” can be used herein interchangeably, and relate to a physical mixture containing a therapeutic compound to be administered to a mammal, e.g. a human, in order to prevent, treat, or control a particular disease or condition affecting a mammal.
- a mammal e.g. a human
- the terms also encompass, for example, an intimate physical mixture formed at high temperature and pressure.
- oral administration represents any method of administration in which a therapeutic compound can be administered through the oral route by swallowing, chewing, or sucking an oral dosage form.
- Such oral dosage forms are traditionally intended to substantially release and/or deliver the active agent in the gastrointestinal tract beyond the mouth and/or buccal cavity.
- a therapeutically effective amount of a compound refers to an amount that will elicit the biological or medical response of a subject, for example, ameliorate symptoms, alleviate conditions, slow or delay disease progression, etc.
- a therapeutically effective amount also refers to an amount of the compound that, when administered to a subject, is effective to at least partially alleviate and/or ameliorate a condition, a disorder, or a disease.
- effective amount means the amount of the subject compound that will engender a biological or medical response in a cell, tissue, organs, system, animal or human that is being sought by the researcher, medical doctor or other clinician.
- low dose can be used interchangeably, and refer to a low amount of the active pharmaceutical ingredient ranging from about 0.001 mg to about 10 mg, preferably to an amount ranging from about 0.1 mg to about 2 mg.
- particle(s) refers to a particle or particles, comprising an (a) inert substrate, and (b) a mixture comprising compound (A), and at least one binder.
- the inert substrate, as disclosed herein, together with the coating defines the size of the particle.
- the particle can have a size from about 20 ⁇ m to about 500 ⁇ m.
- the particle can have a size from about 50 ⁇ m to 400 ⁇ m.
- the particle can have a size of about 100 ⁇ m to about 300 ⁇ m.
- the particle size is measured, for example, by by laser diffraction methodology (e.g. particle size distribution (PSD)), using the equipment described herein.
- PSD particle size distribution
- inert substrate refers to a substance or a material that does not react with neither a chemically or biologically reactive substance, and will not decompose.
- binder is used herein in its established meaning in the field of pharmaceutics. It refers to a non-active substance that is added alongside the active pharmaceutical ingredient (herein referred to as Compound (A)), e.g. adhesion to the inert substrate particles in case of compound (A) deposition or in case of tableting as a promoter of cohesive compacts which enables to form granules and which ensures that granules can be formed with the required mechanical strength. All binders, referred herein, are used in qualities suitable for pharmaceutical use and are commercially available under various brand names as indicated in the following examples:
- Particle type Non-spherical mode
- Example 1 Preparation of Composition Comprising Compound (A) without the Outer Seal Coating Layer
- composition is prepared by first dissolving the binder polyvinyl pyrrolidone (povidone K30), Compound (A), as defined herein, in a polar protic solvent as defined herein to provide an API solution. Said prepared API solution is then sprayed onto an inert substrate, such as lactose or Aeroperl®, in a fluid bed dryer by top spray. The mixture is then dried to remove the solvent to provide Composition comprising Compound (A), in this case a particle.
- Tables 1, 1A, and 2 below illustrate the composition of the particles.
- Formulations 1 and 2 contain Compound (A) at 0.06% and 0.1% w/w (dry basis), respectively.
- Formulation 1 Formulation 2 (F1) (F2) Quantity per Quantity per Material Batch (g) Batch (g) Spray Dried Lactose 2000 2000 API Solution
- Compound (A) 1.20 2.00 Polyvinyl pyrrolidone 1.80 3.00 (Povidone K30) Ethanol* 597 995 Total 600 1000 *The ethanol is then evaporated.
- Formulations 1A and 2A each contains Compound (A) at 0.15% w/w (dry basis).
- Formulation 1A Formulation 2A (F1A) (F2A) Quantity per Quantity per Material Batch (g) Batch (g) Spray Dried Lactose 4155.75 Spray Dried Mannitol 4155.75 API Solution Compound (A) 6.75 6.75 Polyvinyl pyrrolidone 337.50 337.50 (Povidone K30) Ethanol* 4951.90 4951.90 Total 4500 4500 *The ethanol is then evaporated.
- Composition Comprising Compound (A) prepared form an aqueous suspension containing Compound (A) at 2% w/w.
- Formulation 3 Formulation 4 (F3) (F4) Quantity per Quantity per Material Batch (g) Batch (g) Inert substrate (96% w/w)** 9.6 192 Compound (A) (2% w/w) 0.20 4.00 Polyvinyl pyrrolidone 0.20 4.00 (Povidone K30) (2% w/w) Water* Q.S Q.S Total 10 200 *The water has been evaporated. Loss on drying (LOD) ⁇ 2% post processing. **The Inert substrate can be Aeroperl ®.
- the inert substrate such as lactose or Aeroperl®
- the inert substrate was pre-treated with an aqueous hydroxypropyl methylcellulose solution to achieve a granule size uniformity.
- Table 2A shows an example of treating the spray dried lactose with a 5% aqueous solution of HPMC.
- the granules of such surface treated inert substrate was then layered with a solution of Compound (A) at an appropriate concentration, and dried to achieve a loading level of 0.1% to 0.15% of Compound (A) w/w relative to the total dr weight of the composition.
- the pre-treated (granulated) lactose was then coated with the API according to Table 2B below to provide Composition Comprising Compound (A) at 0.1% w/w (dry basis).
- Composition Comprising Compound (A) at 0.1% w/w prepared from granulated lactose.
- Material Quantity per Batch g
- Granulated Lactose 4200.004 API solution
- Polyvinyl pyrrolidone 42.468
- Compound (A) 4.247 Ethanol 1 4642.719 Dry weight 4246.719 1 Removed during manufacturing process.
- the seal coating was performed by spraying a 5% w/w aqueous solution of HPMC onto the particles prepared following Formulation 2 (F2) (see Table 1), to achieve a theoretical weight gain of 3%.
- the Formulation 2 (F2) comprising an outer seal coating is referred to herein as Formulation F2s.
- the sealed coated particles comprising Compound (A) were encapsulated into size 1 capsules.
- the term “capsules” refer to hard gelatin capsules unless otherwise specified.
- Dissolution performance was evaluated to ensure that the dissolution profile matched that of the dry blend formulation (Compound (A), lactose, crospovidone, magnesium stearate) in a capsule.
- the dissolution rate is measured by the conventional method.
- the dissolution rate (%) of C1, C2 and a capsule containing a dry blend comprising 0.1 mg of Compound (A) is plotted over a course of 120 min.
- both dose strengths yielded dissolution greater than two times that of the dry blend formulation at 15 minutes time point.
- the capsule formulation of the pharmaceutical composition has the advantage to provide a formulation with fast dissolution rate, which is about 80% or more, in 20 minutes or less. This dissolution rate would meet the specification for an immediate release formulation whose dissolution rate is represented by “Q+5% Provisional.”
- Tablet dosage forms were developed using the Formulation 2 with a seal coating layer (F2s), as disclosed above in Example 2 and Example 3.
- F2s seal coating layer
- Two formulations were evaluated using a common blend approach and to cover the wide dose range mentioned herein.
- the compression profiles for both compositions were almost identical as outlined in the below examples.
- Formulation 6 at both dose strengths was manufactured in a larger scale and was film coated using standard Opadry® brown film coat.
- Opadry® is a complete film coating system made by Colorcon and it is Colorcon's customized one-step system that combines polymer, plasticizer and pigment in a dry concentrate. The analytical results from these batches are disclosed in Table 6 (below), and are depicted in FIG. 3 , and FIG. 4 .
- Dissolution performance was evaluated to ensure that the dissolution profile matched that of the dry blend formulation (Compound (A) encapsulated in a capsule, same as in Example 3).
- the dissolution rate is measured by the conventional method.
- FIG. 3 and FIG. 4 summarize the dissolution profiles of the tablets comprising the above formulations (Formulation 5 and Formulation 6), compressed at different compression forces (2KN and 11 KN).
- the fast dissolution observed for the capsule formulation was not impacted by the compression of the blend into tablets.
- the dissolution rate observed with the tablet formulations is even faster than the dissolution rate of the capsule formulations.
- the tablet formulations have the advantage to provide a formulation with a dissolution rate of about 85% or more, in 20 minutes or less.
- FIG. 5 shows the XRPD diffractograms for the lactose (commercially available—spray dried grade) as inert substrate, the seal coated Formulation 2 (referred herein as F2s), and the common blend prepared according to Table 5, Formulation 6. Comparing all peaks together, the additional peaks present in the diffractogram of the final blend can be attributed to Mannitol DC ( ⁇ 11.5, 14.6, 16.8, 18.8, 20.5, 21.1, 21.7, 23.4, 25.9, 26.1, 29.5, 30.6, 33.6, 33.7, 33.9, and 36.1° (20 degrees).
- Mannitol DC ⁇ 11.5, 14.6, 16.8, 18.8, 20.5, 21.1, 21.7, 23.4, 25.9, 26.1, 29.5, 30.6, 33.6, 33.7, 33.9, and 36.1° (20 degrees).
- FIG. 6 shows the DSC thermogram used to determine the thermal profile of the sealed coated Formulation 2 (F2s) from about 30° C. to 300° C. at 10° C./minute.
- the thermogram shows two distinct endotherms, which may be attributable to melting of multiple components.
- the first endotherm (onset temperature about 134° C.) is broad, exhibiting both peak fronting and tailing, suggesting at least 3 components are present. Decomposition is evident towards the end of the second endotherm at about 240° C.
- the thermal data generated for the sample is reported in Table 9 below.
- FIG. 7 and FIG. 8 show particle size distribution of the seal coated Formulation 2 (F2s) and the Formulation 6 (F6), which were determined by laser diffraction using dry dispersion. Particle size analysis for each sample was performed in triplicate. The mean particle size data determined for the Dv10, Dv50 and Dv90 are reported in Table 10 below:
- FIGS. 9 to 14 SEM images of each of the above batches are shown in FIGS. 9 to 14 .
- FIG. 10 crystals of Compound (A) are visible relative to FIG. 9 , the Lactose without Compound (A), FIGS. 11 to 14 show the appearance of the Formulation 2 (F2) and the seal coated Formulation F2 (F2s), as disclosed herein, at two different resolutions.
- the seal coated particles of the Formulation 2 (F2s) have a smooth surface compared to the particles of the Formulation 2 (F2) without the seal coating layer. This demonstrates that the seal coating was effective.
- Samples of crystalline Compound (A) and amorphous Compound (A) were prepared from pure compound (A), and were used as a comparison Reference.
- Example 6 Compound (A) for the Treatment of Nonalcoholic Steatohepatitis—Interim Results Based on Baseline Body Mass Index from Phase 2b Study FLIGHT-FXR
- the FLIGHT-FXR (NCT02855164) is a Phase 2, randomized, double-blind, multicenter, placebo-controlled trial with an adaptive design to assess the safety, tolerability, and efficacy of Compound (A) in patients with NASH (nonalcoholic steatohepatitis). Data from Compound (A) 60 ⁇ g, Compound (A) 90 ⁇ g, and placebo arms are provided herein-below.
- Example 7 Absorption, Distribution, Metabolism, and Excretion of Compound (A), Following a Single 1-Mg Oral Dose of [ 14 C] Compound (A) in Healthy Human Subjects
- Compound (A) Faecal excretion of Compound (A) related radioactivity played a major role (approximatively 65% of the total dose) while urinary excretion played a slightly minor role (approximatively 29% of the total dose).
- parent Compound (A) reached a maximum concentration (Cmax) of 33.5 ng/mL with a median Tmax (time the maximum concentration is reached) of 4 hours and eliminated with a half time (t 1/2 ) of 13.5 hours in plasma.
- Unchanged Compound (A) was the principal drug-related component found in the plasma (approximatively 92% of total radioactivity).
- Oxidative metabolism appeared to be the major clearance pathway of Compound (A) as the majority of the radioactivity observed in human excreta consisted of oxidative metabolites.
- Primary phase 1 oxidative pathways included: 1) oxidative O-dealkylation; 2) oxidation at the phenylcyclopropyl isoxazole moiety; 3) oxidation at the benzothiazole and fused ring structure. Metabolites containing multiple oxidative modifications and/or glucuronidation to oxidative products were also observed in human excreta.
- Example 8 In Vivo PK
- the PK profiles of the Compound (A) drug products were evaluated in male beagle dogs according to the following method:
- Drug substance Compound (A);
- S1 hard gelatin capsules
- S2 soft gelatin capsules
- S3 film coated tablets according to the compositions below:
- Feeding status Fasted overnight prior to dose administration. Food was returned to the animals after 4 h sample collection;
- the average plasma concentration profile of the three examples are graphed in FIG. 18 .
- the current invention provides a composition with a superior in vitro dissolution profile of Compound (A) relative to the dry blend composition.
- the superior dissolution is manifested in the higher bioavailability in vivo in the dog as demonstrated here.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
- The present invention relates to the field of pharmacy, particularly to a pharmaceutical composition for oral administration comprising particles, wherein said particles comprise an inert substrate, a mixture comprising a non-bile acid farnesoid X receptor (FXR) agonist, such as 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo [3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one binder. The present invention also relates to a pharmaceutical composition comprising a non-bile acid farnesoid X receptor (FXR) agonist, such as 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo [3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid or a pharmaceutically acceptable salt thereof, and another active pharmaceutical ingredient. The present invention also relates to a process for preparing said pharmaceutical composition for oral administration; and to the use of said pharmaceutical composition in the manufacture of a medicament.
- Nuclear receptors constitute a superfamily of transcriptional regulatory proteins that share structural and functional properties and function as receptors for example steroids, retinoids, vitamin D, and thyroid hormones (Evans et al. Science 1988, 240, 889). The farnesoid X receptor (FXR) is a member of the nuclear hormone receptor superfamily and is primarily expressed in the liver, kidney and intestine (Seol et al. Mol. Endocrinol. 1995, 9, 72-85; Forman et al. Cell 1995, 81, 687-693). It functions as a heterodimer with the retinoid X receptor (RXR) and binds to response elements in the promoters of target genes to regulate gene transcription. The FXR-RXR heterodimer binds with highest affinity to an inverted repeat-1 (IR-1) response element, in which consensus receptor-binding hexamers are separated by one nucleotide. FXR is part of an interrelated process, in that FXR is activated by bile acids (the end product of cholesterol metabolism) (Makishima et al. Science 1999, 284, 1362-1365; Parks et al. Science 1999, 284, 1365-1368; Wang et al. Mol. Cell. 1999, 3, 543-553), which serve to inhibit cholesterol catabolism (Urizar et al. J. Biol. Chem. 2000, 275, 39313-39317). FXR agonists have been explored as therapeutics against non-alcoholic steatohepatitis (NASH).
- The specific non-bile acid FXR agonist 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, is referred to herein as Compound (A). The present invention also relates to:
- The compound was disclosed for the first time in WO 2012/087519 (Example 1, compound 1-IB of the table on page 125) and it is also known under the name LJN452 and under its International Nonproprietary Name (INN) “Tropifexor”. Said compound may be used for the treatment of an FXR mediated disease or disorder. There is a need to provide a commercially viable pharmaceutical composition comprising 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof.
- In addition, the following classes of compounds or therapeutics have been explored to mediate metabolic dysfunctions: glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1RAs) and dipeptidyl peptidase-4 (DPP4) inhibitors, peroxisome proliferator-activated receptor (PPARs) agonists, acetyl-CoA carboxylase (ACC) inhibitors, thyroid hormone receptor β (TRβ) agonists, ketohexokinase (KHK) inhibitors, diacylglycerol Acyltransferase 2 (DGAT2) inhibitors, and sodium-glucose linked transporter (SGLT) inhibitors.
- Other related targets and agents include: anti-inflammatory agents (such as
chemokine receptor 2/5 (CCR2/5) antagonists), and anti-fibrosis agents (such as Galectin-3 inhibitors and Lysyl oxidase-like 2 (LOXL 2) inhibitors). - Because the pathophysiology of NAFLD and NASH is complex and multiple redundant pathways may be implicated, there is a need to provide treatments for nonalcoholic fatty liver disease (NAFLD), NASH and fibrotic/cirrhotic that can address the different aspects of these complex conditions, while demonstrating an acceptable safety and/or tolerability profile.
-
FIG. 1 shows the dissolution profile for Capsule (C1) comprising 0.03 mg Compound (A), as disclosed herein, (500 mL and 900 mL vessels volume). -
FIG. 2 shows the dissolution profile for Capsule (C2) comprising 0.16 mg Compound (A) (900 mL vessels volume). -
FIG. 3 shows the dissolution profile for tablets comprising Formulation 5 (F5) and Formulation 6 (F6) with 0.03 mg of Compound (A), as disclosed herein, compressed at lowest and highest compression forces relative to the dry blend capsule formulation (0.1 mg release profile). -
FIG. 4 shows the dissolution profile for tablets comprising Formulation 5 (F5) and Formulation 6 (F6) with 0.03 mg of Compound (A), as disclosed herein, compressed at lowest and highest compression forces relative to the dry blend capsule formulation (0.1 mg release profile). -
FIG. 5 shows the XRPD diffractograms of the lactose, the common blend of Formulation 6 (F6) and the seal coated Formulation 2 (F2s). -
FIG. 6 shows the DSC thermograms obtained for the seal coated Formulation 2 (F2s). -
FIG. 7 shows the particle size distribution (PSP) of the seal coated Formulation 2 (F2s). -
FIG. 8 shows the particle size distribution (PSP) of the tablet blend of Formulation 6 (F6) of the sealed coated tablet formulation comprising Compound (A). -
FIG. 9 shows the SEM analysis of Lactose (inert substrate without Compound (A)) at 5 μm. -
FIG. 10 shows the SEM analysis of the Formulation 2 (F2) at 5 μm. -
FIG. 11 shows the SEM analysis of the Formulation 2 (F2) at 100 μm -
FIG. 12 shows the SEM analysis of the seal coated Formulation 2 (F2s) at 100 μm. -
FIG. 13 shows the SEM analysis of the Formulation 2 (F2s) at 20 μm. -
FIG. 14 shows the SEM analysis of the sealed coated Formulation 2 (F2s) at 20 μm. -
FIG. 15 shows the surface Raman mapping of the sealed coated Formulation 2 (F2s) at 10 μm resolution. -
FIG. 16 shows the surface Raman mapping of sealed coated Formulation 2 (F2s) at 20 μm resolution. -
FIG. 17 shows the Raman Spectra comparing crystalline and amorphous Compound (A), with Compound (A) in the Formulation 2 (F2) (0-1777 cm−1 range). -
FIG. 18 shows the average plasma concentration over time for Compound (A) in different formulations in the dog. - The design of a pharmaceutical composition, a pharmaceutical dosage form, as well as a commercially viable process to prepare the pharmaceutical composition, for a non-bile acid FXR agonist, such as 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof (herein Compound (A)) is especially challenging. This non-bile acid FXR agonist is a highly potent active pharmaceutical ingredient (API) classified by the biopharmaceutical classification system as a class IV compound, e.g. poorly soluble and poorly permeable compound. Moreover, this non-bile acid FXR agonist is difficult to formulate due to its physicochemical properties and its high potency. Finding a suitable pharmaceutical composition, in a reliable and robust way, proved challenging. For example, due to its very high potency a low dosage is needed (sub-milligrams or micrograms), generating unwanted formulation issues such as content uniformity, and additional manufacturing difficulties, particularly when practiced on a larger manufacturing scale. Furthermore, this non-bile acid FXR agonist has a low water solubility and mixing the compound with conventional excipients to provide an effective composition proved difficult (owing to instability of the formulation, unpredictable dissolution rates and variable bioavailability). Accordingly, a suitable and robust solid pharmaceutical composition overcoming the above problems needs to be developed.
- In view of the above-mentioned difficulties, and considerations, it was surprising to find a way to prepare a stable pharmaceutical composition that allows the preparation of a pharmaceutical composition comprising low amounts of the active compound, avoiding any content uniformity or manufacturing issues.
- In one aspect the present invention relates to a pharmaceutical composition for oral administration comprising (a) an inert substrate, and (b) a mixture comprising 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one binder.
- In one aspect the present invention relates to a pharmaceutical composition for oral administration comprising particles, wherein said particles comprise (a) an inert substrate, and (b) a mixture comprising 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one binder.
- Aspects, advantageous features and preferred embodiments of the present invention summarized in the following items, respectively alone or in combination, contribute to solving the object of the invention.
- Item A1. A pharmaceutical composition for oral administration comprising particles, wherein said particles comprise (a) an inert substrate, and (b) a mixture comprising 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-aza bicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one binder.
- Item A2. The pharmaceutical composition according to item A1, wherein 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, is in amorphous form, crystalline form, or a mixture thereof.
- Item A3. The pharmaceutical composition according to item A1 to A2, wherein 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1] octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid is a free form.
- Item A4. The pharmaceutical composition according to items A1 to A3, wherein the (b) mixture comprising 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one binder, is dispersed onto the (a) inert substrate.
- Item A5. The pharmaceutical composition according to items A1 to A3, wherein the (a) inert substrate is coated with the (b) mixture comprising 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one binder.
- Item A6. The pharmaceutical composition according to any one of items A1 to A5, wherein the (a) inert substrate comprises a material which is selected from the group consisting of lactose, microcrystalline cellulose, mannitol, sucrose, starch, granulated hydrophilic fumed silica, or mixtures thereof.
- Item A7. The pharmaceutical composition according to any one of items A1 to A6, wherein the binder is selected from the group consisting of polyvinyl pyrrolidone, hydroxypropyl cellulose, hypromellose, carboxymethyl cellulose, methyl cellulose, hydroxyethyl cellulose, carboxyethyl cellulose, carboxymethylhydroxyethyl cellulose, polyethylene glycol, polyvinylalcohol, shellac, polyvinyl alcohol-polyethylene glycol co-polymer, or a mixtures thereof.
- Item A8. The pharmaceutical composition according to any one of items A1 to A7, wherein the particles further comprises an outer (c) seal coating layer.
- Item A9. The pharmaceutical composition according to any one of items A1 to A8, wherein the outer (c) seal coating layer is selected from the group consisting of hydroxypropyl methyl cellulose, polyvinyl pyrrolidone, hydroxypropyl cellulose, carboxymethyl cellulose, methyl cellulose, hydroxyethyl cellulose, carboxyethyl cellulose, carboxymethylhydroxyethyl cellulose, polyethylene glycol, polyvinylalcohol, or mixtures thereof.
- Item A10. The pharmaceutical composition according to any one of items A1 to A9, wherein the particles are further formulated into a final dosage form, optionally in the presence of at least one pharmaceutically acceptable excipient, and wherein said final dosage form is a capsule, a tablet, a mini-tablet, a sachet, or a stickpack.
- Item A11. The pharmaceutical composition according to item A10, wherein the final dosage form is a capsule or a tablet.
- Item A12. The pharmaceutical composition according to any one of items A1 to A11, comprising at least one further active pharmaceutical ingredient.
- Item A13. The pharmaceutical composition according to any one of items A1 to A12, wherein the final dosage form comprises 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, in an amount of about 0.01 mg to about 2 mg.
- Item A14. A process for preparing the pharmaceutical composition for oral administration, as defined in items A1 to A13, said process comprising the steps of:
-
- (i) Mixing the (b) mixture comprising 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, with at least one binder, and optionally with at least one polar protic solvent, and
- (ii) Adding said mixture (i) to the (a) inert substrate of the particles.
- Item A15. The process according to item A14, wherein the at least one protic polar solvent is selected from the group consisting of organic solvents, water, or mixtures thereof.
- Item A16. The process according to item A15, wherein the organic solvent is selected from the group consisting of methanol, ethanol, isopropanol, n-propanol, n-butanol, or mixtures thereof.
- Item A17. The process according to item A16, wherein the organic solvent is ethanol.
- Item A18. The process according to items A14 to A17, wherein the solvent is removed at a temperature of 20° C. to 130° C.
- Item A19. The process according to items A14 to A18, wherein the mixture of step (i) is dispersed onto the (a) inert substrate.
- Item A20. The process according to any one of items A14 to A18, wherein the (a) inert substrate is coated with the mixture of step (i).
- Item A21. The process according to any one of items A14 to A20, further comprising the step of adding an outer (c) seal coating layer onto said particles.
- Item A22. The process according to any one of items A14 to A21, comprising the step of further adding at least one additional active pharmaceutical ingredient.
- Items A23. The process according to any one of items A14 to A22, further comprising preparing the final dosage form by optionally mixing the particles with at least one pharmaceutically acceptable excipient.
- Items A24. The process according to any one of items A14 to A23, wherein the at least one pharmaceutically acceptable excipient is selected from the group consisting of lactose, mannitol, microcrystalline cellulose, dicalcium phosphate, polyvinyl pyrrolidone, hydroxypropyl methylcellulose, croscarmellose sodium, crospovidone, sodium starch glycolate, colloidal silicon dioxide, magnesium stearate, sodium stearyl fumarate, or mixtures thereof.
- Item A25. The process according to any one of items A14 to A24, wherein the final dosage form is encapsulated or tableted.
- Item A26. A process for preparing a suspension comprising mixing the (b) mixture comprising 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one binder, with water.
- Item A27. A process for preparing a dispersible solution comprising mixing the (b) mixture comprising 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one binder, with an organic solvent.
- Item A28. A solid dispersion comprising 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one binder.
- Item A29. A dispersible solution comprising 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one binder, in an organic solvent.
- Item A30. The pharmaceutical composition according to any one of items A1 to A13, for use as a medicine.
- Item A31. The pharmaceutical composition according to any one of items A1 to A13, for use in the treatment of cholestasis, intrahepatic cholestatis, estrogen-induced cholestasis, drug-induced cholestasis, cholestasis of pregnancy, parenteral nutrition-associated cholestasis, primary biliary cirrhosis (PBC), non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver cirrhosis, alcohol-induced cirrhosis, cystic fibrosis, or liver fibrosis, preferably for primary biliary cirrhosis (PBS) or non-alcoholic steatohepatitis (NASH).
- Item A32. Use of the pharmaceutical composition for oral administration as defined in items A1 to A13, for the manufacture of a medicament for cholestasis, intrahepatic cholestatis, estrogen-induced cholestasis, drug-induced cholestasis, cholestasis of pregnancy, parenteral nutrition-associated cholestasis, primary biliary cirrhosis (PBC), non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver cirrhosis, alcohol-induced cirrhosis, cystic fibrosis, or liver fibrosis, preferably for primary biliary cirrhosis (PBS) or non-alcoholic steatohepatitis (NASH).
- Item A33. A pharmaceutical composition for oral administration comprising (a) an inert substrate, and (b) a mixture comprising 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-aza bicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one binder.
- Item A34. The pharmaceutical composition according to any one of items A1 to A13, and A33, wherein the inert substrate is present in an amount from about 16-fold w/w to about 6400-fold w/w, from about 100-fold w/w to about 3200-fold w/w, from about 400-fold w/w to about 1600-fold w/w, from about 800-fold w/w to about 1200-fold w/w, from about 900-fold w/w to about 1000-fold w/w based on an amount of the 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-aza bicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof.
- Item A35. The pharmaceutical composition according to any one of items A1 to A13, A33, and A34, wherein the inert substrate is present in an amount about 100-fold w/w, about 300-fold w/w, about 500-fold w/w, about 600-fold w/w, about 700-fold w/w, about 800-fold w/w, about 900-fold w/w, about 1000-fold, about 1200-fold w/w, about 1500-fold w/w based on an amount of the 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-aza bicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof.
- Item A36. The pharmaceutical composition according to any one of items A1 to A13, A33 to A35, wherein the at least one binder in the (b) mixture is present in an amount from about 0.5-fold w/w to about 300-fold w/w, from about 1-fold to about 150 fold w/w, from about 10-fold w/w to 100-fold w/w, from 25-fold w/w to about 75-fold w/w, or from about 40-fold w/w to about 60-fold w/w based on an amount of the 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-aza bicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof.
- Item A37. The pharmaceutical composition according to any one of items A1 to A13, A33 to A36, wherein the binder is polyvinyl pyrrolidone.
- Item A38. The pharmaceutical composition according to any one of items A1 to A13, A33 to A37, wherein the binder is present in an amount from about 10-fold w/w to about 100-fold w/w, or about 50-fold w/w based on an amount of the 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-aza bicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof.
- Item A39. The pharmaceutical composition according to any one of items A1 to A13, A33 to A38, wherein 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-aza bicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof is present in an amount from about 0.05% w/w to about 2.5% w/w, from about 0.07% w/w to about 2% w/w, from about 0.08% w/w to about 1% w/w, from about 0.09% w/w to about 0.5% w/w, or from about 0.1% w/w to about 0.25% w/w relative to a weight of the pharmaceutical composition.
- The present invention provides Composition Comprising Compound A containing Compound A in low amounts. In one embodiment, Composition Comprising Compound A is directly processed into final dosage forms.
- In another embodiment, at least one further active pharmaceutical ingredient Compound (B) is combined with Compound A in a dosage form. Compound (B) is introduced via Composition Comprising Compound B. Compound B can be a solid, or a liquid. Thus, Composition Comprising Compound B can be a particle, a granule, a dispersion (solid or liquid), a tablet, a mini-tablet, a bead, a pellet, a solution, or a mixture thereof. Composition Comprising Compound B can be combined with Composition Comprising Compound A to form Composition Comprising Compounds A and B which is then processed into final dosage forms.
- The effective formulation of a low dose non-bile acid FXR agonist, such as 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, (Compound (A), as disclosed herein), proved difficult. For example, difficulties in weighing the low amount of non-bile acid FXR agonist, content uniformity, formulation, dissolution rate and bioavailability issues were observed. Ultimately, those issues were affecting the manufacturing process and in vivo performance of the pharmaceutical composition.
- Surprisingly, it was found that those challenges can be overcome by preparing a pharmaceutical composition for oral administration comprising (a) an inert substrate, and (b) a mixture comprising a non-bile acid FXR agonist, and at least one binder. According to the present disclosure, the non-bile acid FXR agonist is 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo [3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof (Compound (A)).
- In one aspect, the pharmaceutical composition for oral administration of the present invention is a particle.
- In one aspect the present invention provides a pharmaceutical composition for oral administration comprising particles, wherein said particles comprise (a) an inert substrate, and (b) a mixture comprising Compound (A) (2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof), and at least one binder.
- According to the present invention, Compound (A) can also be present in its free form. The Compound (A), as described herein, may also be present in a crystalline form, in an amorphous form, or a mixture thereof.
- In another aspect, the present invention also provides a pharmaceutical composition for oral administration comprising (a) an inert substrate, and (b) a mixture comprising a non-bile acid FXR agonist, and at least one binder. According to the present disclosure, the non-bile acid FXR agonist is 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo [3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof (Compound (A)).
- According to the present invention, the pharmaceutical composition comprises an (a) inert substrate on which the (b) mixture comprising Compound (A), and at least one binder, is added. The (a) inert substrate comprises a material that does not chemically react to the (b) mixture comprising Compound (A), and at least one binder. The (a) inert substance is, for example, a pharmaceutically acceptable excipient known in the art not to interact chemically or physically with the active substance. Optionally, the (a) inert substrate can also be coated with a layer to protect the (a) inert substrate from any unwanted chemical or physical interaction that may happen during the formulation process. Optionally, the (a) inert substrate can also be treated with an acceptable excipient (for example, a binder) to render certain desirable process qualities, such as particle size and flowability, to the inert substance. The (a) inert substrate may comprise a material, which is selected from the group consisting of lactose, microcrystalline cellulose, mannitol, sucrose, starch, granulated hydrophilic fumed silica, tartaric acid, or mixtures thereof. Preferably, the material may comprise a material selected from the group consisting of lactose, microcrystalline cellulose, mannitol, sucrose, starch, granulated hydrophilic fumed silica, or mixtures thereof. More preferably, the material is lactose, or mannitol. The inert substrate can be present in an amount from about 16-fold w/w to about 6400-fold w/w, from about 100-fold w/w to about 3200-fold w/w, from about 400-fold w/w to about 1600-fold w/w, from about 800-fold w/w to about 1200-fold w/w, from about 900-fold w/w to about 1000-fold w/w based on the amount of Compound (A). In one embodiment, the inert substrate is present in an amount about 100-fold w/w, about 300-fold w/w, about 500-fold w/w, about 600-fold w/w, about 700-fold w/w, about 800-fold w/w, about 900-fold w/w, about 1000-fold, about 1200-fold w/w, about 1500-fold w/w based on the amount of Compound (A) or a pharmaceutically acceptable salt thereof.
- Suitable binders for the (a) inert substance or the (b) mixture can be selected, for example, but not limited to, from the group consisting of cellulose acetate, cellulose fatty acid ester, cellulose nitrates (e.g. nitrocelluloses, nitrowools, Collodion), cellulose ether, ethyl cellulose, carboxymethyl cellulose (e.g. sodium cellulose gum, cellulose gum), methyl cellulose (e.g. cellulose methyl ether, Tylose), methylethyl cellulose, methylhydroxypropyl cellulose, polyvinyl pyrrolidone, hydroxypropyl cellulose, hypromellose (HPMC), hydroxyethyl cellulose, carboxyethyl cellulose, carboxymethyl hydroxyethyl cellulose, polyethylene glycol, polyvinyl alcohol, shellac, polyvinyl alcohol-polyethylene glycol co-polymer, or mixtures thereof. Preferably, the binder is selected from the group consisting of polyvinyl pyrrolidone, hydroxypropyl cellulose, hypromellose, carboxymethyl cellulose, methyl cellulose, hydroxyethyl cellulose, carboxyethyl cellulose, carboxymethyl hydroxyethyl cellulose, polyethylene glycol, polyvinylalcohol, shellac, polyvinyl alcohol-polyethylene glycol co-polymer, or mixtures thereof. More preferably, the binder is polyvinyl pyrrolidone (PVP).
- The at least one binder present in the (b) mixture can be present in an amount from about 0.5-fold w/w to about 300-fold w/w, from about 1-fold to about 150 fold, from about 10-fold w/w to 100-fold w/w, from 25-fold w/w to about 75-fold w/w, or from about 40-fold w/w to about 60-fold w/w based on the amount of Compound (A), or a pharmaceutically acceptable salt thereof. The above-mentioned ranges apply for all the binders as listed above. Preferably, the binder is polyvinyl pyrrolidone. Preferably, the binder is present in an amount from about 10-fold w/w to about 100-fold w/w, from about 25-fold w/w to about 75-fold w/w, or from about 40-fold w/w to about 60-fold w/w based on the amount of Compound (A). More preferably, the binder is present in an amount about 50-fold w/w based on the amount of Compound (A), or a pharmaceutically acceptable salt thereof.
- In accordance with the present invention, the (b) mixture comprising Compound (A), and at least one binder, can be added onto the (a) inert core using different techniques known in the art. For example, the (a) inert core can be sprayed or coated with the (b) mixture, using, for example, spray drying, spray layering, spray dispersing, spray coating, fluid bed drying, fluid bed coating, granulators with spray nozzles, or a combination of those spraying techniques thereof. Preferably, the (b) mixture comprising Compound (A), and at least one binder, is dispersed onto the (a) inert substrate. In another preferred aspect, the (a) inert substrate is coated with the (b) mixture comprising Compound (A), and at least one binder. The (b) mixture comprising Compound (A), and at least one binder, is preferably dispersed or coated onto the (a) inert core as discrete particles, thus, providing a large surface area for instant dissolution despite the poor solubility of the drug. As a result, a fast dissolution rate of Compound (A) can be achieved.
- In accordance with the aspect of the present invention, the particle, as defined herein, optionally further comprises an outer (c) seal coating layer. The outer (c) seal coating layer comprises a material that does not chemically react with the (b) mixture comprising Compound (A), and at least one binder, and protects the (b) mixture, as defined herein, from any unwanted chemical or physical interaction that may happen during the formulation process, e.g. with additives, pharmaceutically acceptable excipients, or any further active pharmaceutical ingredient. The outer (c) seal coating layer also provides an additional barrier for taste masking. The outer (c) seal coating layer can also provide a barrier for gastric or stomach release while allowing for enteric or intestinal release. The outer (c) seal coating layer comprises, for example, hydroxypropyl methyl cellulose (HPMC), magnesium stearate, polyvinyl pyrrolidone, hydroxypropyl cellulose, carboxymethyl cellulose, methyl cellulose, hydroxyethyl cellulose, carboxyethyl cellulose, carboxymethylhydroxyethyl cellulose, polyethylene glycol, polyvinylalcohol, cellulose acetate phthalates (CAP), cellulose acetate trimellitates (CAT), hydroxypropyl methyl cellulose phthalates (HPMCP), hydroxypropyl methyl cellulose acetate succinate (HPMCAS), polyvinyl acetate phthalate (PVAP), methyl methacrylate-methacrylic acid copolymers, cellulose acetate succinate, fatty acids, waxes, shellac, sodium alginate, zein, or mixtures thereof. The outer (c) seal coating layer comprises, for example, hydroxypropyl methyl cellulose, magnesium stearate, polyvinyl pyrrolidone, hydroxypropyl cellulose, carboxymethyl cellulose, methyl cellulose, hydroxyethyl cellulose, carboxyethyl cellulose, carboxymethylhydroxyethyl cellulose, polyethylene glycol, polyvinylalcohol, or mixtures thereof. Preferably, the outer (c) seal coating layer comprises magnesium stearate, hydroxypropyl methyl cellulose, or mixtures thereof. More preferably, the material used for the outer (c) seal coating layer is hydroxypropyl methyl cellulose (HPMC).
- The material used for the outer (c) seal coating layer can be present in an amount of about 0.5% w/w to about 6% w/w based on the total weight of the particles. Preferably, in an amount of 1% w/w to about 5% w/w based on the total weight of the particles. More preferably, in an amount of about 3% w/w based on the total weight of the particles. The above-mentioned ranges apply to all outer (c) seal coating layer materials as listed above.
- According to the present invention, the size of the particle corresponds to the size of the (a) inert substrate, as disclosed herein, together with the coating. For example, the particle can have a size from about 20 μm to about 500 μm. Preferably, the particle can have a size from about 50 μm to 400 μm. More preferably, the particle can have a size of about 100 μm to about 300 μm. The particle size is measured, for example, by laser diffraction methodology (e.g. particle size distribution (PSD)). For example, the particle size is measured using the instrument and method disclosed herein.
- A further aspect of the present invention provides a process for preparing the pharmaceutical composition for oral administration, said process comprising the steps of:
- (i) Mixing the (b) mixture comprising Compound (A) (2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof), with at least one binder, as defined herein, and optionally with at least one polar protic solvent, as defined herein; and
- (ii) Adding said mixture (i) to the (a) inert substrate, as defined herein.
- A further aspect of the present invention provides a process for preparing the pharmaceutical composition for oral administration, said process comprising the steps of:
- (i) Mixing the (b) mixture comprising Compound (A) (2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof), with at least one binder, as defined herein, and optionally with at least one polar protic solvent, as defined herein; and
- (ii) Adding said mixture (i) to the (a) inert substrate, as defined herein, wherein said polar protic solvent, when present, is removed at a temperature of about 20° C. to about 130° C. Preferably, the polar protic solvent is removed at a temperature of about 50° C. to about 110° C. More preferably, at a temperature of about 70° C. to about 100° C.
- A further aspect of the present invention provides a process for preparing the pharmaceutical composition for oral administration comprising particles, as defined herein, said process comprising the steps of:
- (i) Mixing the (b) mixture comprising Compound (A) (2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof), with at least one binder, as defined herein, and optionally with at least one polar protic solvent, as defined herein; and
- (ii) Adding said mixture (i) to the (a) inert substrate of the particles, as defined herein.
- The pharmaceutical composition can comprise particles comprising Compound (A), wherein compound (A) is present from about 0.05% w/w to about 2.5% w/w, from about 0.07% w/w to about 2% w/w, from about 0.08% w/w to about 1% w/w, from about 0.09% w/w to about 0.5% w/w, or from about 0.1% w/w to about 0.25% w/w of Compound (A) relative to the total dry weight of the pharmaceutical composition. For example, at about 0.05%, about 0.06%, about 0.07%, about 0.08%, about 0.09%, about 0.1%, about 0.11%, about 0.12%, about 0.13%, about 0.14%, about 0.15%, about 0.16%, about 0.17%, about 0.18%, about 0.19%, about 0.20%, about 0.3%, about 0.5%, about 1%, about 1.5%, about 2%, or about 2.5% w/w relative to the total dry weight of the composition. Preferably, compound (A) is present from about 0.05% to about 0.25%, or from about 0.08% to about 0.15% w/w relative to the total dry weight of the pharmaceutical composition.
- The at least one protic polar solvent comprises organic solvents, water, or mixtures thereof. Suitable, protic polar organic solvents can be selected from, for example, but not limited to, methanol, ethanol, isopropanol, n-propanol, n-butanol, sec-butanol, iso-butanol, tert-butanol, hexanol, nitromethane, or mixtures thereof. Preferably, the organic solvent is selected from the group consisting of methanol, ethanol, isopropanol, n-propanol, n-butanol, or mixtures thereof. More preferably, the protic polar solvent is water, ethanol, or mixtures thereof. Particularly, the organic solvent is ethanol. The optionally at least one polar protic solvent is evaporated at a temperature of about 20° C. to about 130° C. Preferably, the at least one polar protic solvent is removed at a temperature of about 50° C. to about 110° C. More preferably, at a temperature of about 70° C. to about 100° C.
- Another aspect of the present invention relates to a process for preparing the pharmaceutical composition for oral administration comprising particles, as defined herein, said process comprising the steps of:
- (i) Mixing the (b) mixture comprising Compound (A) (2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof), with at least one binder, as defined herein, and optionally with at least one polar protic solvent, as defined herein; and
- (ii) Adding said mixture (i) to the (a) inert substrate of the particles, as defined herein; wherein said polar protic solvent, when present, is removed at a temperature of about 20° C. to about 130° C. Preferably, the polar protic solvent is removed at a temperature of about 50° C. to about 110° C. More preferably, at a temperature of about 70° C. to about 100° C.
- Another aspect of the present invention relates to a process for preparing the pharmaceutical composition for oral administration comprising particles, as defined herein, said process comprising the steps of:
- (i) Mixing the (b) mixture comprising Compound (A) (2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof), with at least one binder, as defined herein, in the presence of an organic solvent, water, or mixture thereof, as defined herein; and
- (ii) Adding said mixture (i) to the (a) inert substrate of the particles, as defined herein.
- Another aspect of the present invention relates to a process for preparing the pharmaceutical composition for oral administration, as defined herein, wherein the mixture of step (i) is dispersed onto the (a) inert substrate.
- Yet another aspect of the present invention relates to a process for preparing the pharmaceutical composition for oral administration, as defined herein, wherein the (a) inert substrate is coated with the mixture of step (i).
- A further aspect of the present invention relates to a process for preparing the pharmaceutical composition for oral administration, as defined herein, said process further comprising the step of adding an outer (c) seal coating layer onto said particles.
- The (c) seal coating layer, as defined herein, prevents chemical-physical interactions between the particles and any other active or non-active substances that may be used in the preparation of the final dosage form.
- Another aspect of the present invention relates to the process for preparing the pharmaceutical composition for oral administration comprising particles, as defined herein, said process comprising, for example, the steps of:
-
- (i) Mixing the (b) mixture comprising Compound (A), with at least one binder, preferably the binder is polyvinyl pyrrolidone, in the presence of ethanol, to obtain a solution;
- (ii) Adding the solution from step (i) to the (a) inert substrate of the particles, preferably, the (a) inert substrate is lactose or mannitol; and
- (iii) Optionally adding an outer (c) seal coating layer onto said particles, preferably, the (c) seal coating layer is hypromellose (HPMC).
- Another aspect the present invention provides for a process for preparing a dispersible solution comprising mixing the (b) mixture comprising 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one binder with an organic solvent, as defined herein. Preferably, the organic solvent is ethanol.
- Another aspect the present invention relates to a dispersible solution comprising 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo [3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one binder, in an organic solvent.
- Another aspect of the present invention relates to the process for preparing the pharmaceutical composition for oral administration comprising particles, as defined herein, said process comprising, for example, the steps of:
-
- (i) Mixing the (b) mixture comprising Compound (A), with at least one binder, preferably the binder is polyvinyl pyrrolidone, in the presence of water, to obtain a suspension;
- (ii) Adding the suspension from step (i) to the (a) inert substrate of the particles, preferably, the (a) inert substrate comprises a material which is selected from the group consisting of lactose, microcrystalline cellulose, mannitol, sucrose, starch, granulated hydrophilic fumed silica, or mixtures thereof; and
- (iii) Optionally adding an outer (c) seal coated layer onto said particles, preferably, and the (c) seal coated layer is hypromellose (HPMC).
- Another aspect of the present invention provides for a process for preparing a suspension comprising mixing the (b) mixture comprising 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, at least one binder, with water, as defined herein.
- Another aspect of the present invention relates to a solid dispersion comprising 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one binder, in water, as defined herein.
- Another aspect of the present invention also provides for a process, as defined herein, comprising the step of further adding at least one additional active pharmaceutical ingredient.
- Another aspect of the present invention provides for a process further comprising preparing the final dosage form by mixing the particles with at least one pharmaceutically acceptable excipient. The at least one pharmaceutically acceptable excipient can be selected, for example, from the group consisting of lactose, mannitol, microcrystalline cellulose, dicalcium phosphate, polyvinyl pyrrolidone, hydroxypropyl methylcellulose, croscarmellose sodium, crospovidone, sodium starch glycolate, colloidal silicon dioxide, magnesium stearate, sodium stearyl fumarate, or mixtures thereof. Preferably, the excipient can be selected from the group consisting of mannitol, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, or mixtures thereof.
- The pharmaceutical composition comprising Compound A either with or without a binder, an inert substrate, or other excipients is hereafter referred to as Composition Comprising Compound A. In one embodiment, compound (A) or a pharmaceutically acceptable salt thereof is present from about 0.05% to about 2.5%, from about 0.07% to about 2%, from about 0.08% to about 1%, from about 0.09% to about 0.5%, or from about 0.1% to about 0.25% w/w relative to the total weight of Particles Comprising Compound A. For example, at about 0.05%, about 0.06%, about 0.07%, about 0.08%, about 0.09%, about 0.1%, about 0.11%, about 0.12%, about 0.13%, about 0.14%, about 0.15%, about 0.16%, about 0.17%, about 0.18%, about 0.19%, about 0.20%, about 0.3%, about 0.5%, about 1%, about 1.5%, about 2%, or about 2.5% w/w relative to the total eight of Particles Comprising Compound A. Preferably, compound (A) or a pharmaceutically acceptable salt thereof is present from about 0.05% to about 0.25%, or from about 0.08% to about 0.15% w/w relative to the total weight of Composition Comprising Compound A.
- The present disclosure provides a composition, such as a solid composition, comprising Compound B. The identity of Compound B is not particularly limited. In some instances, Compound B itself is a combination of two or more active pharmaceutical ingredients. Compound B can be a solid or a liquid. Thus, Composition Comprising Compound B can be a particle, a granule, a dispersion (solid or liquid), a tablet, a mini-tablet, a bead, a pellet, a solution, or a mixture thereof.
- Compound B may be selected from the following classes of active pharmaceutical ingredients: glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1RAs), dipeptidyl peptidase-4 (DPP4) inhibitors, peroxisome proliferator-activated receptor (PPARs) agonists, acetyl-CoA carboxylase (ACC) inhibitors, thyroid hormone receptor β (TRβ) agonists, ketohexokinase (KHK) inhibitors, diacylglycerol Acyltransferase 2 (DGAT2) inhibitors, sodium-glucose linked transporter (SGLT) inhibitors, anti-inflammatory agents (such as
chemokine receptor 2/5 (CCR2/5) antagonists), and anti-fibrosis agents (such as Galectin-3 inhibitors and Lysyl oxidase-like 2 (LOXL 2) inhibitors). - In addition to Compound B, the composition can have one or more additional ingredients. for example one or more binders, one or more fillers, one or more disintegrants, or one or more lubricants. Further additional ingredients can also be present, although it should be understood that no particular additional ingredient is required.
- The one or more binders are discussed in the context of Composition Comprising Compound A above.
- The one or more fillers, when used, can include at least one of lactose, microcrystalline cellulose, calcium phosphate dibasic anhydrous, calcium phosphate dibasic dihydrate, calcium phosphate tribasic, cellulose powder, magnesium carbonate, calcium sulfate, starch, talc, sucrose, dextrose, mannitol, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, carboxymethylcellulose, fructose, xylitol, sorbitol, and combinations thereof.
- The one or more disintegrants, when used, can include at least one of cross-linked polyvinylpyrrolidone, cross-linked sodium carboxymethyl cellulose, and sodium starch glycolate. For example, the one or more disintegrants can be cross-linked sodium carboxymethyl cellulose. The weight ratio of the one or more disintegrants, such as cross-linked sodium carboxymethyl cellulose, to Compound B is not particularly limited. For example, the one or more disintegrants can be present in an amount of from about 2% to about 10%, such as about 4% to about 8%, or about 6%, by weight of the composition.
- The one or more lubricants, when used, can include at least one of talc, silica, stearin, magnesium stearate, or stearic acid. For example, the one or more lubricants can be magnesium stearate. The one or more lubricants can be present in an amount of from about 0.25% to about 5%, such as from about 0.75% to about 3%, or about 1.25%, by weight of the composition.
- Further additional ingredients that can be used are listed in Remington: The Science and Practice of Pharmacy, which is hereby incorporated by reference in its entirety for all purposes.
- The composition discussed above containing Compound B is referred to as Composition Comprising Compound B (containing Compound B with or without other excipients) hereafter.
- The current invention also provides a fixed dose combination containing Compounds A and B. As discussed above, the effective formulation of low doses of Compound A or a pharmaceutically acceptable salt thereof proved difficult. The current invention overcomes the difficulties in formulating a fixed dose combination composition containing both Compounds A and B by utilizing each of Composition Comprising Compound A and Composition Comprising Compound B as intermediates. The fixed dose combination composition prior to the conversion to a final dosage form is referred to as Composition Comprising Compounds A and B hereafter.
- The current invention provides compatible Composition Comprising Compound A and Composition Comprising Compound B. The free combination of the two allows Compound A and Compound B in a desired proportion according to the desired pharmaceutical and/or therapeutic effects. The compatibility allows ready preparation of unit dosage forms, or multiple-dosage forms from Composition Comprising Compounds A and B.
- As an example, Composition Comprising Compound A and Composition Comprising Compound B are combined (e.g. mixed or blended) in a proportion for a desired therapeutic effect. One or more of the binders, fillers, disintegrants, lubricants, and other additional ingredients discussed above can also be admixed in the combining process. The method of combining is not particularly limited.
- The pharmaceutical composition comprising Composition Comprising Compound (A) may be directly converted into final dosage forms. Alternatively, as discussed above in detail, Composition Comprising Compound (A) may also be combined with Composition Comprising Compound B to form Composition Comprising Compounds A and B which then is processed into final dosage forms.
- Another aspect the present invention provides for a process, as defined herein, wherein the final dosage form is encapsulated or tableted.
- The pharmaceutical composition, as disclosed herein, is intended to be administered orally to humans and animals in unit dosage forms, or multiple-dosage forms, such as, for example, a capsule, a caplet, a powder, pellets, granules, a tablet, a mini-tablet, a sachet, a pouch, or a stick pack. The pharmaceutical composition may contain Compound (A) or also with Compound (B) as described above. Preferably, the unit dosage form, or multi-dosage form, for example, is a capsule, a tablet, a mini-tablet, a sachet, a pouch, or a stick pack. More preferably, the pharmaceutical composition is in the form of a capsule, or a tablet. This can be achieved by mixing the pharmaceutical composition, as defined herein, with diluents, lubricants, binders, disintegrants, and/or absorbents, colorants, flavours and sweeteners.
- Capsules comprising the particles or the compositions of the invention, as defined herein, can be prepared using techniques known in the art. Suitable capsules can be selected from a soft gelatin capsule, a hard shell capsule, a hard gelatin capsule, a plant-based shell capsule, a hypromellose (HPMC) based capsule, or mixtures thereof. The pharmaceutical composition, as described herein, can be presented in a hard gelatin capsule, a soft gelatin capsule, a hard shell capsule, or a hard plant shell capsule, hypromellose (HPMC) capsule wherein the pharmaceutical composition is further mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate, or cellulose-based excipient. The hard gelatin capsules are made of two-piece outer gelatin shells referred to as the body and the cap. The shell may comprise vegetal or animal gelatin (e.g. pork, beef, or fish based gelatin), water, one or more plasticizers, and possibly some preservatives. The capsule may hold a dry mixture, in the form of a powder, very small pellets, or particles, comprising a non-bile acid FXR agonist, such as Compound (A), at least one binder, and optionally excipients. The shell may be transparent, opaque, coloured, or flavoured. The capsules containing the particles can be coated by techniques well known in the art with enteric- and/or gastric-resistant or delayed-release coating materials, to achieve, for example, greater stability in the gastrointestinal tract, or to achieve the desired rate of release. Hard gelatin capsules of any size (
e.g. size 000 to 5) can be prepared. - Tablet comprising the particles of the invention, as defined herein, can be prepared using techniques known in the art. Suitable tablets may contain the particles in admixture with non-toxic pharmaceutical, which are suitable for the manufacture of tablets. These excipients are, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose (e.g. lactose SD), mannitol (e.g. mannitol DC), magnesium carbonate, kaolin, cellulose (e.g. microcrystalline cellulose, powdered cellulose), calcium phosphate, or sodium phosphate; granulating and disintegrating agents, for example, croscarmellose sodium, crospovidone, sodium starch glycolate, corn starch, or alginic acid; gliding agents, for example, fumed silica (e.g. Aerosil®, Aeroperl®); binding agents (e.g. for example, methyl cellulose, carboxymethyl cellulose, polyvinyl pyrrolidone, starch, gelatin, or acacia); and lubricating agents, for example magnesium stearate, sodium stearyl fumarate, stearic acid or talc. The mixture of the particles in admixture with non-toxic pharmaceutical can be mixed using numerous known methods, such as, for example, mixing in a free-ball, or tumble blending. The mixture of the particles in admixture with non-toxic pharmaceutical can be compressed into a tablet using tableting techniques known in the art, such as, for example, a single punch press, a double punch press, a rotary tablet press, or a compaction on a roller compaction equipment. The compression force applied to form the tablet can be any suitable compression force that allows obtaining a tablet, for example, the compression applied can be between 0.5 to 50 kN, preferably between 1 to 30 kN. The tablets can be uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, tablets can be coated with a suitable polymer or a conventional coating material to achieve, for example, greater stability in the gastrointestinal tract, or to achieve the desired rate of release, for example the tablet can be coated with hypromellose (HPMC), magnesium stearate, polyethylene glycol (PEG), polyvinyl alcohol (PVA), Opadry®, Opadry II®, or mixtures thereof. For example, a time delay material such as glyceryl monostearate or glyceryl distearate can be employed. Tablets of any shape or size can be prepared, and they can be opaque, coloured, or flavoured.
- A flow chart depicting the manufacturing process of the pharmaceutical composition comprising Compound (A) is shown below in
Scheme 1. - The inert substrate, such as lactose or mannitol, may be pre-treated to provide a granule so that the particle size is in an acceptable range, for example. The pre-treatment may employ an adequate binder, for example, HPMC and polyvinylpyrrolidone. The pre-treatment granulation can be a dry or wet process. The API such as Compound A is then layered onto the pre-treated inert substrate as described above.
- The non-bile acid FXR agonist, such as Compound (A), alone or in combination with a second active pharmaceutical ingredient, as disclosed herein, are present in the pharmaceutical composition in an amount sufficient to exert a therapeutically useful effect in the absence of undesirable side effects on the patient treated. Due to the high potency of Compound (A), a low dose is preferable. Each unit dose contains a predetermined amount of the Compound (A), sufficient to produce the desired therapeutic effect. Each unit dose as disclosed herein, are suitable for human and animal subjects, are packaged individually and may be administered in fractions or multiples thereof. A multiple-dose form is a plurality of identical unit-dosage forms packaged in a single container to be administered in segregated unit-dose form. Examples of multiple-dose forms include vials, blisters, or bottles.
- In accordance with the present invention, Compound (A) or its pharmaceutically acceptable salt may be present in the pharmaceutical composition for oral administration in a low amount. In one aspect of the present invention relates to a pharmaceutical composition for oral administration wherein the final dosage form comprises Compound (A) or its pharmaceutically acceptable salt, in an amount of about 0.01 mg to about 2 mg, about 0.03 mg to about 1.5 mg, about 0.05 mg to about 1 mg, or about 0.07 mg to about 0.09 mg. Preferably, the low amount of the non-bile acid FXR agonist, such as Compound (A), is about 0.01 mg, or about 0.02 mg, or about 0.03 mg, or about 0.04 mg, or about 0.05 mg, or about 0.06 mg, or about 0.07 mg, or about 0.08 mg, or about 0.09 mg, or about 0.1 mg, or about 0.12 mg, or about 0.14 mg, or about 0.15 mg, or about 0.2 mg, or about 0.25 mg, or about 0.5 mg, or about 0.8 mg, or about 1 mg, or about 1.2 mg, or about 1.4 mg, or about 1.5 mg, or about 1.8 mg, or about 2 mg. More particularly, the amount is about 0.01 mg, or is about 0.03 mg, or is about 0.09 mg, or is about 0.1 mg, or is about 0.12 mg, or is about 0.14 mg, or is about 0.25 mg, or is about 0.5 mg, or is about 1 mg, or is about 1.5 mg, or the amount is about 2 mg. More preferably, the amount is about 0.01 mg, or is about 0.03 mg, or is about 0.09 mg, or is about 0.1 mg, or is about 0.5 mg, or the amount is about 2 mg.
- A further aspect of the invention relates to a pharmaceutical composition for oral administration, as defined herein, comprising at least one further active pharmaceutical ingredient Compound (B) in a therapeutically effective amount.
- The pharmaceutical composition for oral administration, as disclosed herein, is useful, for example, as medicine, for the treatment of an FXR mediated condition or disorder such as, for example, cholestasis, intrahepatic cholestatis, estrogen-induced cholestasis, drug-induced cholestasis, cholestasis of pregnancy, parenteral nutrition-associated cholestasis, primary biliary cirrhosis (PBC), non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver cirrhosis, alcohol-induced cirrhosis, cystic fibrosis, or liver fibrosis. Specifically, the present disclosure provides the use of said pharmaceutical composition in the treatment of primary biliary cirrhosis (PBS), or non-alcoholic steatohepatitis (NASH).
- Accordingly, the final dosage form for oral administration, prepared from the pharmaceutical composition of the current invention, is useful, for example, as medicine, for the treatment of an FXR mediated condition or disorder such as, for example, cholestasis, intrahepatic cholestatis, estrogen-induced cholestasis, drug-induced cholestasis, cholestasis of pregnancy, parenteral nutrition-associated cholestasis, primary biliary cirrhosis (PBC), non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver cirrhosis, alcohol-induced cirrhosis, cystic fibrosis, or liver fibrosis. Specifically, the present disclosure provides the use of said pharmaceutical composition in the treatment of primary biliary cirrhosis (PBS), or non-alcoholic steatohepatitis (NASH).
- Another aspect of the invention also provides for the use of the pharmaceutical composition, as disclosed herein, for the manufacture of a medicament for cholestasis, intrahepatic cholestatis, estrogen-induced cholestasis, drug-induced cholestasis, cholestasis of pregnancy, parenteral nutrition-associated cholestasis, primary biliary cirrhosis (PBC), non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver cirrhosis, alcohol-induced cirrhosis, cystic fibrosis, or liver fibrosis, preferably for primary biliary cirrhosis (PBS), or non-alcoholic steatohepatitis (NASH). Specifically, the present disclosure provides the use of said pharmaceutical composition in the treatment of primary biliary cirrhosis (PBS), or non-alcoholic steatohepatitis (NASH).
- Another aspect of the invention also provides for a method of treating a disease or disorder in a patient in need thereof, wherein the disease or disorder is cholestasis, intrahepatic cholestatis, estrogen-induced cholestasis, drug-induced cholestasis, cholestasis of pregnancy, parenteral nutrition-associated cholestasis, primary biliary cirrhosis (PBC), non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver cirrhosis, alcohol-induced cirrhosis, cystic fibrosis, or liver fibrosis, comprising the step of administering to the patient an effective amount of the pharmaceutical composition or the final dosage form. Specifically, the present disclosure provides a method of treating primary biliary cirrhosis (PBS), or non-alcoholic steatohepatitis (NASH).
- The term “farnesoid X receptor” or “FXR” refers to all mammalian forms of such receptors including, for example, alternative splice isoforms and naturally occurring isoforms (Huber et al. Gene, 2002, 290, 35). Representative farsenoid X receptor species include, without limitation, the rat (GenBank Accession No. NM_021745), the mouse (GenBank Accession No. NM_009108), and the human (GenBank Accession No. NM_005123) forms of the receptor.
- The term “non-bile acid FXR agonist” refers to an agent that directly binds to and upregulates the activity of non-bile acid FXRs. Particularly, the term “agonist” refers to an agent that triggers at least one response by binding a non-endogenous ligand to the receptor. The agonist may act directly or indirectly with a second agent that itself modulates the activity of the receptor. The agonist may also act indirectly by modulating the activity of one or more agent(s) that modulate the amount of FXR mRNA or FXR protein in certain cells of a patient.
- The term “pharmaceutically acceptable salts” refers to salts that can be formed, for example, as acid addition salts, preferably with organic or inorganic acids. For isolation or purification purposes it is also possible to use pharmaceutically unacceptable salts, for example picrates or perchlorates. For therapeutic use, only pharmaceutically acceptable salts or free compounds are employed (where applicable in the form of pharmaceutical preparations), and these are therefore preferred. The term “pharmaceutically acceptable” refers to those compounds, materials, compositions, and/or dosage forms which are suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, other problem or complication, commensurate with a reasonable benefit/risk ratio.
- The term “treat”, treating” or “treatment” of any disease or disorder refers to ameliorating the disease or disorder (e.g. slowing, arresting or reducing the development of the disease, or at least one of the clinical symptoms thereof), to preventing, or delaying the onset, or development, or progression of the disease or disorder. In addition those terms refer to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient and also to modulating the disease or disorder, either physically (e.g. stabilization of a discernible symptom), physiologically (e.g. stabilization of a physical parameter), or both.
- The term “about”, as used herein, is intended to provide flexibility to a numerical range endpoint, providing that a given value may be “a little above” or “a little below” the endpoint accounting for variations one might see in the measurements taken among different instruments, samples, and sample preparations. The term usually means within 10%, preferably within 5%, and more preferably within 1% of a given value or range.
- The terms “pharmaceutical composition” or “formulation” can be used herein interchangeably, and relate to a physical mixture containing a therapeutic compound to be administered to a mammal, e.g. a human, in order to prevent, treat, or control a particular disease or condition affecting a mammal. The terms also encompass, for example, an intimate physical mixture formed at high temperature and pressure.
- The term “oral administration” represents any method of administration in which a therapeutic compound can be administered through the oral route by swallowing, chewing, or sucking an oral dosage form. Such oral dosage forms are traditionally intended to substantially release and/or deliver the active agent in the gastrointestinal tract beyond the mouth and/or buccal cavity.
- The term “a therapeutically effective amount” of a compound, as used herein, refers to an amount that will elicit the biological or medical response of a subject, for example, ameliorate symptoms, alleviate conditions, slow or delay disease progression, etc. The term “a therapeutically effective amount” also refers to an amount of the compound that, when administered to a subject, is effective to at least partially alleviate and/or ameliorate a condition, a disorder, or a disease. The term “effective amount” means the amount of the subject compound that will engender a biological or medical response in a cell, tissue, organs, system, animal or human that is being sought by the researcher, medical doctor or other clinician.
- The term “comprising” is used herein in its open ended and non-limiting sense unless otherwise noted. In a more limited embodiment “comprising” can be replaced by “consisting of”, which is no longer open-ended. In a most limited version it can include only feature steps, or values as listed in the respective embodiment.
- The terms “low dose”, “low dosage strength”, or “low amount”, as used herein, can be used interchangeably, and refer to a low amount of the active pharmaceutical ingredient ranging from about 0.001 mg to about 10 mg, preferably to an amount ranging from about 0.1 mg to about 2 mg.
- The term “particle(s)”, as used herein, refers to a particle or particles, comprising an (a) inert substrate, and (b) a mixture comprising compound (A), and at least one binder. The inert substrate, as disclosed herein, together with the coating defines the size of the particle. For example, the particle can have a size from about 20 μm to about 500 μm. Preferably, the particle can have a size from about 50 μm to 400 μm. More preferably, the particle can have a size of about 100 μm to about 300 μm. The particle size is measured, for example, by by laser diffraction methodology (e.g. particle size distribution (PSD)), using the equipment described herein.
- The term “inert substrate”, as used herein, refers to a substance or a material that does not react with neither a chemically or biologically reactive substance, and will not decompose.
- The term “binder”, is used herein in its established meaning in the field of pharmaceutics. It refers to a non-active substance that is added alongside the active pharmaceutical ingredient (herein referred to as Compound (A)), e.g. adhesion to the inert substrate particles in case of compound (A) deposition or in case of tableting as a promoter of cohesive compacts which enables to form granules and which ensures that granules can be formed with the required mechanical strength. All binders, referred herein, are used in qualities suitable for pharmaceutical use and are commercially available under various brand names as indicated in the following examples:
-
- Polyvinyl pyrrolidone (INN Ph. Eur.) is commercially available under the trade name Povidone K30 or PVP K30 (approximate molecular weight 50 000).
- Shellac (INN Ph. Eur.) is a commercially available resin excreted by the females of the insects Laccifer lacca Kerr, Kerria lacca Kerr, Tachardia lacca, Coccus lacca and Carteria lacca on various trees. Shellac composition is as follows: 46% Aleuritic acid (HOCH2(CH2)5CHOHCHOH(CH2)7COOH), 27% Shellolic acid (a cyclic dihydroxy dicarboxylic acid and its homologues), 5% Kerrolic acid (CH3(CH2)10(CHOH)4COOH), 1% Butolic acid (C14H28(OH)(COOH)), 2% Esters of wax alcohols and acids, 7% Non-identified neutral substances (e.g. coloring substances, etc), and 12% Non-identified polybasic esters.
- Polyvinyl alcohol (INN Ph. Eur.) is commercially available under the trade name Polyviol or PVA (approximate
molecular weight 28 000 to 40 000). - Polyethylene glycol (Ph. Eur.) is commercially available under the trade name PEG-n, where “n” is the number of ethylene oxide units (EO-units) (approximate molecular weight up to 20 000).
- Polyvinyl alcohol-polyethylene glycol co-polymer also known as polyvinyl alcohol-PEG copolymer.
- % w/w Percent weight by weight
- ALT alanine aminotransferase
- API Active pharmaceutical ingredient
- AV Acceptance value
- BMI Body mass index
- C4 7-hydroxy-4-cholesten-3-one
- CAP Cellulose acetate phthalates
- CAT Cellulose acetate trimellitates
- CU Content uniformity
- DAD Diode array detector
- DSC Differential Scanning Calorimetry
- FGF fibroblast growth factor
- FXR Farsenoid X receptor
- g/min Gram per minute
- GGT gamma-glutamyl transferase
- HCl Hydrochloric acid
- HDL-C High-density lipoprotein cholesterol
- HPMC Hypromellose/hydroxypropylmethyl cellulose
- HPMCAS Hydroxypropyl methyl cellulose phthalates
- INCI International Nomenclature of Cosmetic Ingredients
- INN International nonproprietary name
- Kg/g/mg/ng/μg Kilogram/Gram/Milligram/Nanogram/Microgram
- kN Kilo Newton
- LC (%) Percent of label claim
- LDL-C low-density lipoprotein cholesterol
- LFC liver fat content
- LOS Loss on drying
- m3/h Cubic meter per hour
- mbar millibar
- mL/L Milliliters/Liters
- MRI-PDFF magnetic resonance imaging-proton density fat fraction
- N Normal
- NAFLD Non-alcoholic fatty liver disease
- NASH Non-alcoholic steatohepatitis
- ° C. Degree Celsius
- PBC Primary biliary cirrhosis
- PEG Polyethylene glycol
- Ph. Eur. European Pharmacopoeia (9th edition)
- PSD Particle Size Distribution
- PVA Polyvinyl alcohol
- PVAP Polyvinyl acetate phthalate
- Q (%) Amount of active released
- Q.S Quantity sufficient
- RH Relative humidity
- RSD Relative standard deviation
- Sec/msec Seconds/milliseconds
- SEM Scanning Electron Microscopy
- TFA Trifluoroacetic acid
- TG triglycerides
- USP United States Pharmacoepia
- UV Ultra Violet
- w/v weight by volume
- w/w weight by weight
- XRPD X-ray Powder Diffraction
- The following examples illustrate the invention and provide support for the disclosure of the present invention without limiting the scope of the invention.
- Analytical Details
-
- Dissolution conditions: The dissolution analysis were performed using a USP II (paddles) apparatus in a medium comprising 0.5% w/v sodium lauryl sulfate in 0.1N HCl, at a temperature of 37.0±0.5° C. Analysis were performed in a 900 ml vessel or in a 500 ml vessel.
- Assay and degradation: The analysis was performed using the following Column: Agilent pursuit XRs 3 μm C18 150×3 mm,
column temperature 30° C.
- Detection: UV or DAD
- Gradient: Eluant A: 0.05% TFA in water/Eluant B: 0.05% acetonitrile
-
Time [min] % A (Eluent A) % B (Eluent B) 0.0 86 14 15.3 14 86 20.4 14 86 20.5 0 100 24.0 0 100 24.1 86 14 30.0 86 14 -
- Content uniformity: The content uniformity analysis was performed using the following: Column: Kinetex XB-
C18% 5 μm 150×4.6,column temperature 30° C.
- Content uniformity: The content uniformity analysis was performed using the following: Column: Kinetex XB-
- Detection: UV or DAD
- Eluant A: 0.05% TFA in water/Eluant B: 0.05% acetonitrile (no gradient).
-
- XRPD: The X-Ray Powder Diffraction (XRPD) analysis was performed using a Panalytical Xpert Pro diffractometer equipped with a Cu X-ray tube and a Pixcel detector system, using a monochromatic Cu(Kα)-radiation. About 20 mg of each material was analyzed at ambient temperature in transmission mode held between low density polyethylene films. The Instrument parameters are as follows:
-
Sample prep Transmission foil Range: 3-40° 2θ degrees Step size: 0.013° Counting time: (Step time) ~90 s Run time: 20 min Incident Optics Soller slits: 0.02 rad Mirror: Beam Cu W/Si focusing MPD Divergence slit: ½° Antiscatter slit: ½° NO Beam attenuator, Mask or Filter Diffracted Optics Detector: PIXcel Soller slits: Large 0.02 rad Antiscatter slit: AS slit 7.5 mm Pixcel -
- DSC: Differential Scanning Calorimetry (DSC) analysis was carried out using a Perkin Elmer Jade DSC system. The sample was weighed into an aluminum pan and a lid was crimped into position. The sample was heated under a nitrogen environment from about 30° C. to 300° C. using a heating rate of 10° C./minute.
- PSD: Particle size distribution was determined using the Malvern Mastersizer 3000 (MS3000) equipped with an Aero S dry dispersion unit and micro tray. The Instrument parameters are as follows:
- Lens/measuring range: 0.01 μm-3500 μm
- Analysis sensitivity: Normal
- Calculation model: Mie (material refractive index: 1.540, absorption: 0.01)
- Particle type: Non-spherical mode
- Obscuration filtering: Yes_Obscuration limits: 0.10-6.00%
- Feed rate: 45%
- Disperser pressure: 2.2 bar
- Auto start measurement: yes_Background measurement: 20 seconds
-
- Sample measurement: 10 seconds
- Raman Spectrometry: The Raman spectrometry was recorded on a Witec Alpha 300 confocal Raman imaging system using 633 nm and a Laser Helium-Neon (HeNe) 35 mW. The Instrument parameters are as follows:
- Laser wavelength: 532
- Laser intensity (mA): 22
- Integration Time (s): 0.6
- Objective lens: 40×/0.6 Korr
- Grating value: 600
- Optical resolution (μm): 1
- The composition is prepared by first dissolving the binder polyvinyl pyrrolidone (povidone K30), Compound (A), as defined herein, in a polar protic solvent as defined herein to provide an API solution. Said prepared API solution is then sprayed onto an inert substrate, such as lactose or Aeroperl®, in a fluid bed dryer by top spray. The mixture is then dried to remove the solvent to provide Composition comprising Compound (A), in this case a particle. Tables 1, 1A, and 2 below illustrate the composition of the particles.
-
TABLE 1 Preparation of Composition Comprising Compound (A) from an ethanolic solution. Formulations (A) at 0.06% and 0.1% w/w (dry basis), respectively. Formulation 1Formulation 2 (F1) (F2) Quantity per Quantity per Material Batch (g) Batch (g) Spray Dried Lactose 2000 2000 API Solution Compound (A) 1.20 2.00 Polyvinyl pyrrolidone 1.80 3.00 (Povidone K30) Ethanol* 597 995 Total 600 1000 *The ethanol is then evaporated. -
TABLE 1A Preparation of Composition Comprising Compound (A) from an ethanolic solution. Formulations 1A and 2A each contains Compound (A) at 0.15% w/w (dry basis). Formulation 1A Formulation 2A (F1A) (F2A) Quantity per Quantity per Material Batch (g) Batch (g) Spray Dried Lactose 4155.75 Spray Dried Mannitol 4155.75 API Solution Compound (A) 6.75 6.75 Polyvinyl pyrrolidone 337.50 337.50 (Povidone K30) Ethanol* 4951.90 4951.90 Total 4500 4500 *The ethanol is then evaporated. -
TABLE 2 Composition Comprising Compound (A) prepared form an aqueous suspension containing Compound (A) at 2% w/w. Formulation 3 Formulation 4 (F3) (F4) Quantity per Quantity per Material Batch (g) Batch (g) Inert substrate (96% w/w)** 9.6 192 Compound (A) (2% w/w) 0.20 4.00 Polyvinyl pyrrolidone 0.20 4.00 (Povidone K30) (2% w/w) Water* Q.S Q.S Total 10 200 *The water has been evaporated. Loss on drying (LOD) <2% post processing. **The Inert substrate can be Aeroperl ®. - Alternatively, the inert substrate, such as lactose or Aeroperl®, was pre-treated with an aqueous hydroxypropyl methylcellulose solution to achieve a granule size uniformity. Table 2A shows an example of treating the spray dried lactose with a 5% aqueous solution of HPMC. The granules of such surface treated inert substrate was then layered with a solution of Compound (A) at an appropriate concentration, and dried to achieve a loading level of 0.1% to 0.15% of Compound (A) w/w relative to the total dr weight of the composition.
-
TABLE 2A Pre-treatment of spray dried lactose to provide granulated lactose. Material Quantity per Batch (g) Spray Dried Lactose 4496.520 HPMC solution (5% w/w) Hydroxy propyl methyl cellulose 112.411 Purified water 2135.813 1Removed during manufacturing process. - The pre-treated (granulated) lactose was then coated with the API according to Table 2B below to provide Composition Comprising Compound (A) at 0.1% w/w (dry basis).
-
TABLE 2B Composition Comprising Compound (A) at 0.1% w/w prepared from granulated lactose. Material Quantity per Batch (g) Granulated Lactose 4200.004 API solution (1% w/w) Polyvinyl pyrrolidone 42.468 Compound (A) 4.247 Ethanol1 4642.719 Dry weight 4246.719 1Removed during manufacturing process. - Composition Comprising Compound (A), prepared according to any of the formulation examples (F1, F2, F3 and F4) disclosed in Example 1, were then seal coated.
- For example, the seal coating was performed by spraying a 5% w/w aqueous solution of HPMC onto the particles prepared following Formulation 2 (F2) (see Table 1), to achieve a theoretical weight gain of 3%. The Formulation 2 (F2) comprising an outer seal coating is referred to herein as Formulation F2s.
- During spraying a visual inspection was performed every 30 minutes to ensure no agglomeration was occurring during the process.
- To assess the content uniformity of each batch, the sealed coated particles comprising Compound (A) (e.g. as disclosed in Example 2) were encapsulated into
size 1 capsules. The term “capsules” refer to hard gelatin capsules unless otherwise specified. -
- Capsules (C1) comprising 30 up of Compound (A): In order to manufacture final dosage forms, such as capsules, containing 30 μg of Compound (A), 51.7 mg of the particles from Example 1 (Formulation 1 (F1)) was blended with 1% magnesium stearate and filled into a
capsule size 1. The total weight of Compound (A) (drug load) was 0.058% of the capsule. The fill weight was adjusted accordingly. - Capsules (C2) comprising 160 μg of Compound (A): In the same manner, the final dosage forms, such as capsules, containing 160 μg dose of Compound (A), were manufactured using 166.7 mg of the particles from Example 1 (Formulation 2 (F2)) blended with 1% magnesium stearate and filled into a
capsule size 1. The total weight of Compound (A) (drug load) was 0.096% of the capsule. The fill weight was adjusted accordingly.
- Capsules (C1) comprising 30 up of Compound (A): In order to manufacture final dosage forms, such as capsules, containing 30 μg of Compound (A), 51.7 mg of the particles from Example 1 (Formulation 1 (F1)) was blended with 1% magnesium stearate and filled into a
- Based on the final compositions and process parameters established from the examples outlined above, confirmatory capsule batches were manufactured using the same conditions for stability evaluation. Assay testing was performed separately on:
-
- Particles comprising Compound (A) without the seal coating layer (F1 and F2)
- Particles comprising Compound (A) and a seal coat (F1s and F2s)
- Encapsulation was performed using the MG2 Labby encapsulation machine. Capsules were packaged in 30 count bottles for the stability study. The results from the confirmatory batches, including the content uniformity (CU) results, are shown in Table 3 and Table 4 below:
-
TABLE 3 Content uniformity results for the 30 μg capsule (C1) batch F1 + outer seal Formulation 1 (F1) coating (=F1 s) Sample % w/w % LC % w/ w % LC 1 0.0576 96.1 0.0552 95.2 2 0.0586 97.7 0.0566 97.5 3 0.0615 102.4 0.0544 93.8 4 0.0559 93.2 0.0534 92.0 5 0.0535 89.1 0.0529 91.2 6 0.0581 96.9 0.0536 92.3 Mean 0.0580 95.9 0.054 93.7 % RSD 4.7 4.7 2.5 2.5 Filter 0.0571 95.1 0.1008 173.7 Blend filled Capsule C1 (=F1 + outer seal coating) Sample % LC 1 94.1 2 94.7 3 97.0 4 94.3 5 93.9 6 95.3 7 96.9 8 95.8 9 96.7 10 96.4 Mean 95.5 % RSD 1.2 AV 5.8 -
TABLE 4 Content uniformity results for the 160 μg capsule (C2) batch F2 + outer seal Formulation 2 (F2) coating (=F2 s) Sample % w/w % LC % w/ w % LC 1 0.0870 87.0 0.0967 99.6 2 0.0942 94.2 0.0947 97.5 3 0.0969 96.9 0.1040 107.1 4 0.0958 95.8 0.0924 95.2 5 0.0915 91.5 0.0927 95.5 6 0.0879 87.9 0.0907 93.4 Mean 0.092 92.2 0.095 98.1 % RSD 4.5 4.5 5.0 5.0 Filter 0.1066 106.6 0.1645 169.4 Blend filled Capsule C2 (=F2 + outer seal coating) Sample % LC 1 97.7 2 98.5 3 98.0 4 98.3 5 97.6 6 98.1 7 97.7 8 97.4 9 97.5 10 98.8 Mean 97.9 % RSD 0.5 AV 1.7 - As it can be seen in Table 3 and Table 4, the content uniformity results are well in the acceptable range for both the 30 μg and 160 μg dose strengths of the filled capsules. This proves a scale-able and commercially viable process was developed. In addition, both capsule strengths (C1 and C2) were tested for stability up to 12 weeks and were found to be stable with no apparent trends of change at 40° C./75% RH for both physical (dissolution) and chemical integrity.
- Dissolution performance was evaluated to ensure that the dissolution profile matched that of the dry blend formulation (Compound (A), lactose, crospovidone, magnesium stearate) in a capsule. The dissolution rate is measured by the conventional method. In
FIGS. 1 and 2 , the dissolution rate (%) of C1, C2 and a capsule containing a dry blend comprising 0.1 mg of Compound (A) is plotted over a course of 120 min. As can be seen inFIG. 1 andFIG. 2 , both dose strengths yielded dissolution greater than two times that of the dry blend formulation at 15 minutes time point. Thus, the capsule formulation of the pharmaceutical composition has the advantage to provide a formulation with fast dissolution rate, which is about 80% or more, in 20 minutes or less. This dissolution rate would meet the specification for an immediate release formulation whose dissolution rate is represented by “Q+5% Provisional.” - Tablet dosage forms were developed using the
Formulation 2 with a seal coating layer (F2s), as disclosed above in Example 2 and Example 3. Preliminary investigations to identify scalable and commercially viable tablet formulations indicated that a direct compression process was feasible. Two formulations were evaluated using a common blend approach and to cover the wide dose range mentioned herein. The compression profiles for both compositions were almost identical as outlined in the below examples. -
TABLE 5 Tablet formulations Formulation 5 (F5) Formulation 6 (F6) mg/ mg/ mg/ mg/ tablet tablet tablet tablet Material % 30 μg 160 μg g/ batch % 30 μg 160 μg g/ batch Formulation 2 51.54 30.93 164.95 154.64 51.54 30.93 164.95 154.64 sealed coated (F2 s)* Drug Load 0.05 0.03 0.16 0.05 0.03 0.16 Compound (A) Lactose SD 28.45 17.07 91.05 85.36 15 9 48 45 Mannitol DC 15 9 48 45 28.45 17.07 91.05 85.36 Croscarmellose 3 1.80 9.60 9 3 1.80 9.60 9 Sodium (Ac-Di-Sol) Aerosil 1 0.60 3.20 3 1 0.60 3.20 3 Magnesium 1 0.60 3.20 3 1 0.60 3.20 3 Stearate Total 100 60 320 300 100 60 320 300 *Drug load Compound A = 0.097% - Formulation 6 at both dose strengths was manufactured in a larger scale and was film coated using standard Opadry® brown film coat. Opadry® is a complete film coating system made by Colorcon and it is Colorcon's customized one-step system that combines polymer, plasticizer and pigment in a dry concentrate. The analytical results from these batches are disclosed in Table 6 (below), and are depicted in
FIG. 3 , andFIG. 4 . -
TABLE 6 Dissolution and content uniformity results of the film coated tablet Compound (A) 30 μg Compound (A) 160 μg film coated tablets film coated tablets Test Specification Tablet 1 (T1) Tablet 2 (T2) Assay 90.0-110.0% of Label Claim (LC) 104.28% 104.10% Time Point Dissolution As per USP <711> 15 min 102 100 and Ph. Eur. 2.9.3 30 min 104 103 (Q = 70%) after 90 45 min 104 103 minutes 60 min 104 103 75 min 104 103 90 min 104 103 120 min 104 103 Content Uniformity (CU) Preparation Content Uniformity of 1 104.52 105.21 Uniformity Dosage Units (by 2 103.97 103.99 Content Uniformity) 3 103.46 101.64 must comply with 4 101.71 102.90 Eur. Ph. 2.9.40 5 102.76 101.60 Acceptance Value 6 103.30 102.22 (AV) less than or 7 101.72 102.80 equal to 15.0 8 103.07 101.89 9 103.41 103.24 10 102.49 101.30 Mean 103.0 102.7 RSD % 0.8 1.2 AV 3.7 4.1 - Dissolution performance was evaluated to ensure that the dissolution profile matched that of the dry blend formulation (Compound (A) encapsulated in a capsule, same as in Example 3). The dissolution rate is measured by the conventional method.
FIG. 3 andFIG. 4 summarize the dissolution profiles of the tablets comprising the above formulations (Formulation 5 and Formulation 6), compressed at different compression forces (2KN and 11 KN). The fast dissolution observed for the capsule formulation (seeFIG. 1 andFIG. 2 ) was not impacted by the compression of the blend into tablets. Surprisingly, the dissolution rate observed with the tablet formulations is even faster than the dissolution rate of the capsule formulations. As it can be seen inFIG. 3 andFIG. 4 , the tablet formulations have the advantage to provide a formulation with a dissolution rate of about 85% or more, in 20 minutes or less. - Both strengths (30 μg and 160 μg) made using Formulation 6 were film-coated and stability assays were performed on the corresponding film-coated tablets (Tablet 1 (T1) and Tablet 2 (T2) as seen in Table 6). The results are depicted in Table 7 and Table 8 below.
-
TABLE 7 Assay stability data of Tablet 1 (T1) Time (weeks) 0 3 6 24 40° C./75% RH 104.3% 103.6% 104.6% 103.9% Dissolution* 104% 105% 106% 103% *As per (USP<711> and Ph. Eur. 2.9.3) Q = 70% after 90 minutes -
TABLE 8 Assay stability data of Tablet 2 (T2) Time (weeks) 0 3 6 24 40° C./75% RH 104.1% 103.5% 105.2% 105.3% Dissolution* 103% 103% 103% 102% *As per (USP<711> and Ph. Eur. 2.9.3) Q = 70% after 90 minutes - After 24 weeks, the stability results, as shown in Table 7 and Table 8, confirm the stability of the drug product and no degradation is observed. As can be seen in Table 7 and Table 8, the dissolution performance of the film-coated tablet is not compromised even under these conditions.
- Differential Scanning Calorimetry (DSC), Particle Size Distribution (PSD) and X-ray Powder Diffraction (XRPD), Scanning Electron Microscopy (SEM) analysis, and Raman spectrometry were carried out on the materials used for the development of the tablet formulations comprising Compound (A), as depicted in
Formulation 5 and Formulation 6. These experiments helped to characterize and determine the physical nature of Compound (A). -
FIG. 5 shows the XRPD diffractograms for the lactose (commercially available—spray dried grade) as inert substrate, the seal coated Formulation 2 (referred herein as F2s), and the common blend prepared according to Table 5, Formulation 6. Comparing all peaks together, the additional peaks present in the diffractogram of the final blend can be attributed to Mannitol DC (˜11.5, 14.6, 16.8, 18.8, 20.5, 21.1, 21.7, 23.4, 25.9, 26.1, 29.5, 30.6, 33.6, 33.7, 33.9, and 36.1° (20 degrees). -
FIG. 6 shows the DSC thermogram used to determine the thermal profile of the sealed coated Formulation 2 (F2s) from about 30° C. to 300° C. at 10° C./minute. The thermogram shows two distinct endotherms, which may be attributable to melting of multiple components. The first endotherm (onset temperature about 134° C.) is broad, exhibiting both peak fronting and tailing, suggesting at least 3 components are present. Decomposition is evident towards the end of the second endotherm at about 240° C. The thermal data generated for the sample is reported in Table 9 below. -
TABLE 9 DSC thermal data obtained for the sealed coated formulation F2 (F2 s) Endotherm 1 (° C.) Endotherm 2 (° C.) Sample Onset Heat Peak Onset Heat Peak Descrip- Temp. Flow Temp. Temp. Flow Temp. tion (° C.) (J/g) (° C.) (° C.) (J/g) (° C.) F2 s 134.48 140.5300 140.60 209.99 278.2691 218.56 -
FIG. 7 andFIG. 8 show particle size distribution of the seal coated Formulation 2 (F2s) and the Formulation 6 (F6), which were determined by laser diffraction using dry dispersion. Particle size analysis for each sample was performed in triplicate. The mean particle size data determined for the Dv10, Dv50 and Dv90 are reported in Table 10 below: -
TABLE 10 Particle size data determined for the particle made according to the Formulation 2 (F2) and the Formulation 6 μm Material Prep# Dv10 Dv50 Dv90 Seal Coated 1 115.669 173.540 254.715 Formulation 22 117.853 169.732 241.322 (F2 s) 3 120.457 173.614 248.519 Mean 117.99 172.30 248.19 % RSD 2 1 3 Formulation 6 1 60.253 153.844 261.210 (F6) 2 67.160 152.807 255.700 3 66.476 151.540 257.340 Mean 64.63 152.73 258.08 % RSD 6 1 1 - The XRPD and DSC results alone were unable to distinguish the physical nature of Compound (A) due to the extremely low drug concentration of 0.1% and the presence of other excipients especially in the blend used for the tablet dosage form. In view of this, additional investigations were conducted, such as SEM analysis.
- The SEM analysis was performed on the following samples:
-
- Lactose (commercially available—spray dried grade)
-
Formulation 2, as disclosed herein - Seal Coated Formulation 2 (F2s)
- SEM images of each of the above batches are shown in
FIGS. 9 to 14 . InFIG. 10 , crystals of Compound (A) are visible relative toFIG. 9 , the Lactose without Compound (A),FIGS. 11 to 14 show the appearance of the Formulation 2 (F2) and the seal coated Formulation F2 (F2s), as disclosed herein, at two different resolutions. The seal coated particles of the Formulation 2 (F2s) have a smooth surface compared to the particles of the Formulation 2 (F2) without the seal coating layer. This demonstrates that the seal coating was effective. - To confirm the crystalline nature of the drug, Raman microscopy and analysis were investigated to determine the spatial distribution on the (a) inert substrate, in this case lactose. This study aimed at determining the spatial distribution of compound (A), in the Formulation 2 (F2), once dispersed onto the inert substrate (drug load of 0.1% and PVPK30 as binder). A suitable amount of particles were deposited onto a microscopy slide and a single surface Raman mappings (150×150 μm2-1 μm resolution/0.6 s second integration time) was performed.
- Scanning the sample surface and mapping Raman spectra across the scanned area showed clearly defined (microparticle-like) areas where spectra could be associated with crystalline Compound (A), while in-between those areas the Raman spectra were associated with excipients (binder, carrier) only (as seen in
FIG. 15 andFIG. 16 ). - Samples of crystalline Compound (A) and amorphous Compound (A) were prepared from pure compound (A), and were used as a comparison Reference.
-
- The crystalline Compound (A) was prepared according to well known in the art crystallisation technique.
- Amorphous Compound (A) was prepared as followed: 30 mg of Compound (A) was dissolved in 1.5 mL of dioxane in 2 separate vials. The vials were shock frozen in dry ice. Lyophilisation was performed overnight, using techniques well known in the art, until amorphous Compound (A) was obtained. The amorphous sample was analysed using XRPD/DSC.
- Those samples were analysed by Raman spectroscopy (see
FIG. 17 , so called “Compound (A) crystalline reference” and “Compound (A) amorphous reference”). Raman spectra of reference crystalline Compound (A) and amorphous Compound (A) were compared to that of Compound (A) extracted from the Formulation 2 (F2). As seen inFIG. 17 , Compound (A) layered onto the inert substrate (e.g lactose), according to the Formulation 2 (F2), exhibits clear correlation with the Raman fingerprint of “Compound (A) crystalline reference” in terms of characteristic Raman peak positions. Thus, showing that Compound (A) can also be present in a crystalline form in the pharmaceutical composition. - The FLIGHT-FXR (NCT02855164) is a
Phase 2, randomized, double-blind, multicenter, placebo-controlled trial with an adaptive design to assess the safety, tolerability, and efficacy of Compound (A) in patients with NASH (nonalcoholic steatohepatitis). Data from Compound (A) 60 μg, Compound (A) 90 μg, and placebo arms are provided herein-below. - Patients were divided into two subgroups: Lower BMI subgroup (BMI <30 kg/m2 (Asian) or <35 kg/m2 (Non-Asian)) and Higher BMI subgroup (BMI ≥30 kg/m2 (Asian) or >35 kg/m2 (Non-Asian))
- The objectives of the study were as follows:
-
- To determine the dose-response relationship of compound (A) on a marker of FXR target engagement in the gut (FGF19) by BMI subgroups over time.
- To determine dose-response relationship of compound (A) on markers of hepatic inflammation (alanine aminotransferase [ALT]), target engagement and marker of oxidative stress (gamma-glutamyl transferase [GGT]), and on changes in liver fat content (LFC) measured by magnetic resonance imaging proton density fat fraction (MRI-PDFF) at
Week 12 by BMI subgroups. - To determine lipids profile by BMI subgroups.
-
TABLE 11 Study population Key inclusion criteria Key exclusion criteria Male and female patients aged ≥18 years, History of liver transplantation weighing ≥40 and ≤150 kg Liver fat content ≥10% at screening Uncontrolled diabetes mellitus (DM) defined as HbA1c ≥9.5% within 60 days prior to enrolment Presence of NASH was defined by: Prior diagnosis of other forms of chronic liver Liver biopsy consistent with NASH and disease, presence of cirrhosis on liver biopsy, fibrosis level F1, F2, or F3, obtained 2 years or clinical diagnosis of cirrhosis and/or platelet or less prior to randomisation, no diagnosis of count <120 × 109/L or severe liver impairment alternate chronic liver disease and elevated Current or history of significant alcohol ALT (≥43 IU/L [males] or ≥28 IU/L [females]) consumption (male, >30 g/day; female, >20 OR g/day, on average) for a period of >3 consecutive months within 1 year prior to Phenotypic diagnosis based on all of the screening and/or a score on the AUDIT following: elevated ALT (≥43 IU/L [males] questionnaire ≥8 or ≥28 IU/L [females]), BMI ≥27 kg/m2 (in Pregnant or nursing patients with a self-identified race other than (lactating) mothers Asian) or ≥23 kg/m2 (in patients with a self- Previous exposure to obeticholic acid identified Asian race), and diagnosis of Type 2 diabetes mellitus (DM) by having either glycocylated haemoglobin (HbA1c) ≥6.5% or drug therapy for Type 2 DM - Results and Efficacy of 60 μg Compound (A), 90 μg Compound (A), and Placebo
- Table 12 (below) shows the results observed in each treatment arms.
-
TABLE 12 Geometric mean percentage change in markers of efficacy (FGF19 (4 hours post-dose from pre-dose at Week 6) and all others parameters from baseline to Week 12)) by BMI subgroups (with N, total number of patients) Lower BMI† Higher BMI‡ Compound (A), Compound (A), Compound (A), Compound (A), Placebo 60 μg 90 μg, Placebo 60 μg 90 μg Parameters, % N = 28 N = 21 N = 52 N = 18 N = 16 N = 33 FGF19 21.5 360.2 585.8 68.0 276.9 446.9 C4 2.8 −33.2 −40.4 37.3 −48.9 −61.8 GGT −10.8 −47.0 −61.3 −6.8 −38.4 −48.7 ALT −18.6 −26.0 −26.8 −10.6 −14.8 −19.5 LFC§ −13.1 −19.9 −18.8 −5.5 −12.9 −11.4 HDL-C −4.8 −1.9 −7.7 −3.9 −6.1 −11.9 TG 1.2 0.9 5.7 0.9 −6.7 −2.3 †BMI < 30 kg/m2 (Asian) or <35 kg/m2 (Non-Asian); ‡BMI ≥ 30 kg/m2 (Asian) or ≥35 kg/m2 (Non-Asian); §Measured by MRI-PDFF -
- Effect of Compound (A) on marker of target engagement: FGF19: the assessment of FGF19 was done at Week 6. A dose-response increase in the FGF19 levels was observed 4 hours post-dose compared with pre-dose in both BMI subgroups. At Week 6, the geometric mean percentage changes in FGF19 from pre-dose in the lower BMI subgroup (60 μg of Compound (A)=360.2, and 90 μg of Compound (A)=585.8) were higher than the mean percentage changes in the higher BMI subgroup (60 μg of Compound (A)=276.9, and 90 μg of Compound (A)=446.9).
- Effect of Compound (A) on marker of hepatic inflammation: ALT: A rapid and sustained decline in ALT levels from baseline was observed with 90 μg of Compound (A) doses in patients from both BMI subgroups, more marked in the group with lower BMI.
- Effect of Compound (A) on GGT, a marker of oxidative stress: A dose-response decrease in GGT levels was observed with Compound (A) in both BMI subgroups, more marked in the group with lower BMI. At
Week 12, the geometric mean percentage change in GGT was higher with 60 μg of Compound (A) (−47.0) and 90 μg of Compound (A) (−61.3) in the lower BMI versus 60 μg of Compound (A) (−38.4) and 90 μg of Compound (A) (−48.7) in the higher BMI subgroup. - Effect of Compound (A) on liver fat content: At
Week 12, the mean percentage change was greater in all arms in the lower BMI subgroup (placebo=−13.1; Compound (A) 60 μg=−19.9, and Compound (A) 90 μg=−18.8) compared with the higher BMI subgroup (placebo=−5.5; Compound (A) 60 μg=−12.9, and Compound (A) 90 μg=−11.4). The proportion of patients with an absolute decrease of Liver fat content (LFC) by >5% was higher in the lower BMI subgroup versus the higher BMI subgroup. - Effect of Compound (A) on C4: At
Week 12, a decrease of 7-hydroxy-4-cholesten-3-one (C4) was observed in all Compound (A) treatment groups. This decrease is more obvious in the higher BMI subgroup. However, C4 is subject to diurnal variation, therefore, the influence of BMI on C4 invites further investigation.
- As far as the safety of the formulation comprising Compound (A) is concerned, the Incidence of adverse events, including pruritus, was comparable between arms. Lipid profiles were comparable in both BMI subgroups. The interim results from the first two parts of this Phase 2b study provide the evidence for target engagement, anti-inflammatory, and antisteatotic effects of Compound (A) in both BMI subgroups. However, the effect of Compound (A) on ALT, GGT, and LFC was more pronounced in the lower BMI subgroup. The study also showed that the lipid profiles were comparable in both subgroups and that rates of events in the study, including pruritus, were comparable across treatment arms. Consistent trends of lower responses in the higher BMI subgroup, receiving lower dosing by body weight, support testing higher Compound (A) doses (e.g. 140 and 200 μg/day).
- Absorption, distribution, metabolism, and excretion of Compound (A) was studied following a single 1-mg oral dose of [14C]Compound (A) to four healthy human subjects. The rate and route of excretion of [14C]Compound (A) related radioactivity was determined as well as pharmacokinetic profiles of Compound (A) and of total radioactivity in plasma. The key biotransformation pathways and clearance mechanisms of [14C]Compound (A) in human were elucidated. Mass balance was achieved with approximately 94% of the administered dose recovered in excreta through the 312 hours collection period. Faecal excretion of Compound (A) related radioactivity played a major role (approximatively 65% of the total dose) while urinary excretion played a slightly minor role (approximatively 29% of the total dose). After oral administration of 1 mg [14C]Compound (A) to human subjects, parent Compound (A) reached a maximum concentration (Cmax) of 33.5 ng/mL with a median Tmax (time the maximum concentration is reached) of 4 hours and eliminated with a half time (t1/2) of 13.5 hours in plasma. Unchanged Compound (A) was the principal drug-related component found in the plasma (approximatively 92% of total radioactivity). Two minor oxidative metabolites, were observed in circulation, at approximatively 2% and approximatively 5% of the total drug radioactivity exposure, respectively. Compound (A) was eliminated predominantly via metabolism with more than 68% of the dose recovered as metabolites in excreta. Oxidative metabolism appeared to be the major clearance pathway of Compound (A) as the majority of the radioactivity observed in human excreta consisted of oxidative metabolites.
Primary phase 1 oxidative pathways included: 1) oxidative O-dealkylation; 2) oxidation at the phenylcyclopropyl isoxazole moiety; 3) oxidation at the benzothiazole and fused ring structure. Metabolites containing multiple oxidative modifications and/or glucuronidation to oxidative products were also observed in human excreta. - The PK profiles of the Compound (A) drug products were evaluated in male beagle dogs according to the following method:
- Drug substance: Compound (A);
- Drug products: S1—hard gelatin capsules, S2—soft gelatin capsules, and S3—film coated tablets according to the compositions below:
-
mg/unit S1 Compound (A) 0.03 Lactose 28.92 Crospovidone 0.9 Magnesium stearate 0.15 Capsule 48 S2 Compound (A) 0.03 Propylene glycol monolaurate 139.97 Glycerol 35.64 Gelatin 67.49 Purified water 48.53 Titanium dioxide 1.52 Glycerol 1.52 Purified water 0.3 S3 Formulation 2 30.09 (30 μg Compound (A)) Lactose 9 Mannitol 17.1 Croscarmellose Sodium 1.8 Silicon dioxide 0.6 Magnesium stearate 0.6 HPMC Coating 5 - Species, strain, sex: beagle dog, male (n=4), crossover;
- Route of administration: Oral (pentagastrin pre-treatment (6 μg/kg i.m.) 30 min prior to dosing);
- Feeding status: Fasted overnight prior to dose administration. Food was returned to the animals after 4 h sample collection;
- Dose: 30 μg/animal/dose;
- Sample collected: K2-EDTA Blood (plasma analyzed);
- Sampling time points: 0.25, 0.5, 1, 2, 3, 5, 8, 24, 28 and 32 h post dose;
- Sample analysis: LC-MS/MS with positive electrospray ionization.
- The PK results are summarized in Table 13 below.
-
TABLE 13 PK properties of certain embodiments of the invention Drug Product S1 S2 S3 Dose 0.00313 ± 0.000439 0.00313 ± 0.000445 0.00315 ± 0.000470 Tmaxa (h) 3.0 [2-24] 3.0 [2-8] 3.0 [2-5] Tlasta (h) 32 [32-32] 32 [32-32] 32 [32-32] Cmax (ng/mL) 1.71 ± 0.740 2.89 ± 0.871 3.37 ± 0.974 Cmax/dose 57.0 ± 24.7 96.4 ± 29.0 112 ± 32.5 (ng/mL)/(mg) AUClast (h*ng/mL) 24.1 ± 6.65 43.9 ± 6.71 36.2 ± 5.60 AUClast/dose 802 ± 222 1460 ± 224 1210 ± 187 (hr*ng/mL/mg) AUCinf (h*ng/mL) 27.5 ± 7.60 46.7 ± 7.64 41.6 ± 4.56 AUCinf/dose 916 ± 253 1560 ± 255 1390 ± 152 (h*ng/mL)/(mg) Bioavailability (%) 100 192 ± 49.8 157 ± 38.6 aMedian [range]. - The average plasma concentration profile of the three examples are graphed in
FIG. 18 . As shown in Examples 3 and 4, the current invention provides a composition with a superior in vitro dissolution profile of Compound (A) relative to the dry blend composition. The superior dissolution is manifested in the higher bioavailability in vivo in the dog as demonstrated here.
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/668,811 US20220233515A1 (en) | 2019-03-13 | 2022-02-10 | Pharmaceutical Composition |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962817795P | 2019-03-13 | 2019-03-13 | |
US201962850781P | 2019-05-21 | 2019-05-21 | |
US16/815,183 US11291661B2 (en) | 2019-03-13 | 2020-03-11 | Pharmaceutical composition |
US17/668,811 US20220233515A1 (en) | 2019-03-13 | 2022-02-10 | Pharmaceutical Composition |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/815,183 Continuation US11291661B2 (en) | 2019-03-13 | 2020-03-11 | Pharmaceutical composition |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220233515A1 true US20220233515A1 (en) | 2022-07-28 |
Family
ID=70057177
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/815,183 Active US11291661B2 (en) | 2019-03-13 | 2020-03-11 | Pharmaceutical composition |
US17/668,811 Abandoned US20220233515A1 (en) | 2019-03-13 | 2022-02-10 | Pharmaceutical Composition |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/815,183 Active US11291661B2 (en) | 2019-03-13 | 2020-03-11 | Pharmaceutical composition |
Country Status (10)
Country | Link |
---|---|
US (2) | US11291661B2 (en) |
EP (1) | EP3937906A1 (en) |
JP (1) | JP2022524820A (en) |
KR (1) | KR20210139326A (en) |
CN (1) | CN113645961A (en) |
AU (1) | AU2020237662A1 (en) |
CA (1) | CA3132928A1 (en) |
IL (1) | IL285728A (en) |
TW (1) | TW202100152A (en) |
WO (1) | WO2020183388A1 (en) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU24152B1 (en) * | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 OXAZOL-8-AZABICICLO [3,2,1] OCTANO 8 IL AS FXR MODULATORS |
US10077268B2 (en) * | 2014-03-13 | 2018-09-18 | Salk Institute For Biological Studies | FXR agonists and methods for making and using |
KR102338085B1 (en) * | 2016-03-31 | 2021-12-10 | 장피트 | Methods of treatment of cholestatic disease |
CN111183360A (en) * | 2017-07-19 | 2020-05-19 | 生物辐射欧洲有限公司 | Biomarker combination for simultaneous assessment of non-alcoholic steatohepatitis and hepatic fibrosis status |
-
2020
- 2020-03-11 JP JP2021554751A patent/JP2022524820A/en active Pending
- 2020-03-11 US US16/815,183 patent/US11291661B2/en active Active
- 2020-03-11 KR KR1020217032442A patent/KR20210139326A/en unknown
- 2020-03-11 CA CA3132928A patent/CA3132928A1/en active Pending
- 2020-03-11 AU AU2020237662A patent/AU2020237662A1/en not_active Abandoned
- 2020-03-11 CN CN202080020362.0A patent/CN113645961A/en active Pending
- 2020-03-11 EP EP20715465.9A patent/EP3937906A1/en not_active Withdrawn
- 2020-03-11 WO PCT/IB2020/052152 patent/WO2020183388A1/en unknown
- 2020-03-11 TW TW109108003A patent/TW202100152A/en unknown
-
2021
- 2021-08-19 IL IL285728A patent/IL285728A/en unknown
-
2022
- 2022-02-10 US US17/668,811 patent/US20220233515A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA3132928A1 (en) | 2020-09-17 |
US20210169866A1 (en) | 2021-06-10 |
CN113645961A (en) | 2021-11-12 |
EP3937906A1 (en) | 2022-01-19 |
TW202100152A (en) | 2021-01-01 |
KR20210139326A (en) | 2021-11-22 |
WO2020183388A1 (en) | 2020-09-17 |
JP2022524820A (en) | 2022-05-10 |
AU2020237662A1 (en) | 2021-09-30 |
US11291661B2 (en) | 2022-04-05 |
IL285728A (en) | 2021-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11266630B2 (en) | Oral preparation of glucokinase activator and preparation method therefor | |
RU2743637C2 (en) | Pharmaceutical composition containing one or more esters of fumaric acid in a decomposable matrix | |
ES2496144T5 (en) | Pirfenidone capsule formulation and pharmaceutically acceptable excipients | |
TWI520735B (en) | Stabilized pharmaceutical compositions comprising fesoterodine | |
US10441585B2 (en) | Formulations containing nalbuphine and uses thereof | |
ES2292819T3 (en) | PHARMACEUTICAL COMPOSITIONS THAT INCLUDE MYCOPHENOLIC ACID OR MYCOPHENOLATE SALT. | |
US11020412B2 (en) | Pharmaceutical composition comprising dapagliflozin | |
US20100255089A1 (en) | Pharmaceutical Compositions and Methods of Using Same | |
US9364541B2 (en) | Pharmaceutical compositions comprising Fesoterodine | |
AU2003289320C1 (en) | Solid drug for oral use | |
JP2022514569A (en) | Amorphous sparsentan composition | |
NO20240297A1 (en) | Co-crystals | |
US6726929B1 (en) | Pharmaceutical mixture comprising a profen | |
US11291661B2 (en) | Pharmaceutical composition | |
KR100774774B1 (en) | A sustained release preparation of metformin and manufacturing method thereof | |
WO2020109319A1 (en) | Pharmaceutical composition comprising ramipril and indapamide | |
Jubie et al. | Stability enhancement and formulation development of L-Carnitine fast-dissolving pellets through pro-drug strategy | |
RU2734970C1 (en) | System for delivery of 2-ethyl-6-methyl-3-hydroxypyridine succinate for oral administration in form of gastroretentive tablet | |
JP7195354B2 (en) | Pharmaceutical formulation containing one or more fumarates in an eroding matrix | |
US20220401425A1 (en) | Chidamide pharmaceutical composition, preparation method therefor and application thereof | |
TR2022013356A2 (en) | ORAL THERAPEUTIC FORMULATIONS | |
EP4395827A1 (en) | Co-crystals | |
TR2022013352A2 (en) | ORAL PHARMACEUTICAL FORMULATIONS | |
TR2022013357A2 (en) | ORAL THERAPEUTIC FORMULATIONS | |
KR20210098248A (en) | Composite tablet comprising vildagliptin and metformin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: NOVARTIS PHARMACEUTICALS CORPORATION, NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KUMAR, SARAN;REEL/FRAME:059894/0659 Effective date: 20190717 Owner name: NOVARTIS AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS PHARMA AG;REEL/FRAME:059894/0977 Effective date: 20190903 Owner name: NOVARTIS AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS PHARMACEUTICALS CORPORATION;REEL/FRAME:059894/0832 Effective date: 20190718 Owner name: NOVARTIS PHARMA AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GOGNIAT, GEOFFREY;MEIER, ULRICH;RENTSCH, MARIO;SIGNING DATES FROM 20190715 TO 20190730;REEL/FRAME:059894/0316 Owner name: NOVARTIS PHARMA AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GOGNIAT, GEOFFREY;MEIER, ULRICH;RENTSCH, MARIO;SIGNING DATES FROM 20190715 TO 20190730;REEL/FRAME:059894/0444 Owner name: NOVARTIS AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS PHARMACEUTICALS CORPORATION;REEL/FRAME:059894/0880 Effective date: 20190718 Owner name: NOVARTIS AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS PHARMA AG;REEL/FRAME:059894/0917 Effective date: 20190903 Owner name: NOVARTIS PHARMACEUTICALS CORPORATION, NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KUMAR, SARAN;REEL/FRAME:059894/0776 Effective date: 20190717 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |